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ABSTRACT 
 
Bailey Zwarycz: Extrinsic Regulation of Intestinal Stem Cell Proliferation and 
Differentiation by Niche Components 
 (Under the direction of Scott T. Magness) 
 
The small intestinal epithelium facilitates the absorption of nutrients and provides 
a barrier against damaging toxins, indigestible contents, and microbes in the intestinal 
lumen. The epithelium is maintained by a pool of intestinal stem cells (ISCs) that reside 
at the base of the crypt in a supportive niche environment, made up of both cellular and 
non-cellular components. Niche cells, including epithelial Paneth cells, subepithelial 
myofibroblasts, and immune cells, along with the non-cellular extracellular matrix (ECM) 
provide cues that promote ISC proliferation and differentiation. The niche environment is 
complex and dynamic, with various cell types present that secrete different growth factors 
and cytokines in response to intestinal damage, inflammation, and regeneration.  
 Extrinsic niche factors are integral for the survival and proliferation of ISCs; 
therefore, understanding the influence of individual niche components on ISC behavior is 
essential for the development of therapeutics for patient health. Here, two components of 
the ISC niche are investigated for their influence on ISC proliferation and differentiation: 
cytokines secreted from local immune cells and the underlying ECM scaffold. Through a 
screen of inflammatory bowel disease-related cytokines, Interleukin 22 demonstrated a 
concentration-dependent effect on ileal organoid size and survival in vitro. Elevated levels 
of Interleukin 22 limited ISC expansion in favor of increased progenitor cell differentiation 
 iv 
and proliferation, resulting in increased organoids size and expression of antimicrobial 
gene products. ISC cultures rely on the use of non-intestinal based ECM components for 
the survival of ISCs in vitro. Using a natural, acellular intestinal scaffold provides a more 
physiologically relevant substrate for use both in vitro culture systems and for tissue 
engineering applications. By optimizing decellularization techniques, an acellular porcine 
small intestinal scaffold was created that retained mucosal architecture, preserved key 
ECM components, and supported the proliferation and differentiation of mouse small 
intestinal epithelium. Together, these to findings further the understanding of how 
extrinsic factors from the niche influence ISCs, which is of particular importance when 
developing therapies for intestinal disease. 
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CHAPTER 1: INTRODUCTION 
 
Small Intestinal Epithelium: Structure, Function, and Cellular Composition 
 In the gastrointestinal tract, the small intestine specializes in the digestion and 
absorption of food and nutrients. Although all regions of the gastrointestinal tract are 
integral for efficient food and water intake, digestion, and absorption, the focus of this 
dissertation will be on the small intestine. The small intestine is divided into three distinct 
anatomical segments: the duodenum, jejunum, and ileum. The first segment is the 
duodenum where intestinal contents mix with digestive enzymes from the pancreas and 
liver after exiting the stomach. The next, and longest, segment is the jejunum, which is 
the main segment for nutrient absorption. Finally, the ileum is the most distal segment of 
the small intestine and functions to absorb remaining nutrients and bile acids before 
intestinal contents move into the large intestine.  
All three regions – the duodenum, jejunum, and ileum – share a similar layered 
anatomy with an outermost serosa, followed by the muscularis propria (layers of 
longitudinal and circular muscle), submucosa, and innermost mucosa (Figure 1.1A)1. The 
mucosa is comprised of the innermost epithelium and is supported by the lamina propria 
and the muscularis mucosae, a thin smooth muscle layer. In direct contact with the luminal 
contents, the simple monolayer of columnar epithelium facilitates the absorption of 
nutrients and provides a barrier between the rest of the body and indigestible luminal 
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contents, damaging toxins, and microbes that reside in the intestinal lumen. The lamina 
propria resides directly underneath the epithelium and contains supportive structural 
components, including a complex and highly patterned extracellular matrix (ECM) 
architecture, vasculature, mesenchymal cells, and immune cells that directly support 
epithelial structure and function2. In particular, subepithelial myofibroblasts and immune 
cells are in close contact with the epithelium and secrete growth factors and cytokines to 
influence epithelial cell function.  
The epithelium of the small intestine is distinctly organized into a crypt-villus 
architecture (Figure 1.1A). Crypts are invaginations of the epithelium embedded into the 
lamina propria and contain mostly proliferative cells. Epithelial proliferation occurs within 
the crypt and is driven by intestinal stem cells (ISCs) residing at the base. ISCs rapidly 
divide approximately once every 24 hours3 and self-renew to give rise to more ISCs or 
differentiate to a proliferative transit-amplifying (TA) progenitor cell with each division. TA 
progenitor cells divide 2-3 times every 12-16 hours4 and migrate away from the base of 
the crypt before terminally differentiating as they exit the crypt. Crypts surround large, 
finger-like projections called villi, which contain differentiated cells and protrude into the 
intestinal lumen to increase absorptive surface area. 
Differentiated cells migrate from the crypt to the tip of the villus, where they 
ultimately undergo anoikis (a programmed cell death process triggered by loss of contact 
with the basement membrane) and are sloughed off into the intestinal lumen5,6. This 
process of differentiation and migration takes approximately 3-5 days and is integral to 
maintaining epithelial barrier integrity7. In the mouse, there are approximately 6-12 crypts 
per villus depending on the location within the small intestine8, providing a constant 
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“conveyer belt” of differentiated cells for each villus. Regional differences in epithelial 
architecture and differentiated cell composition are also found along the small intestine to 
meet functional requirements. Villi in the duodenum are longest to facilitate nutrient 
absorption and increased secretion of hydrolytic enzymes, whereas villi in the ileum are 
shorter and contain more mucus-secreting cells to facilitate passage of food into the 
colon9,10. 
 
Genes and Pathways Regulating Epithelial Cell Differentiation 
By the time an epithelial cell has migrated to the villus, its identity has been 
established based on gene expression signatures. There are two main lineages of 
differentiated cells – absorptive cells and secretory cells (Figure 1.1B). The initial fate 
decision committing a nascent epithelial cell to an absorptive versus secretory identity is 
strongly controlled by Notch signaling. Notch signaling activates expression of hes family 
bHLH transcription factor 1 (Hes1), which in turn represses the expression of atonal bLHL 
transcription factor 1 (Atoh1). Under homeostatic Notch signaling, the majority of epithelial 
cells differentiate towards the absorptive lineage and become enterocytes. Similarly, 
Atoh1 deletion results in differentiation towards enterocytes11,12. Approximately 80% of 
the cells on the villus are enterocytes, which absorb nutrients though their apical brush 
border13. Enterocytes also provide hydrolytic brush border enzymes to facilitate the 
breakdown of dietary carbohydrates and proteins and can therefore be identified by their 
expression of enzymes including sucrose isomaltase (SI) and lactase. 
Inhibition of Notch signaling, or overexpression of Atoh1, causes differentiation 
towards a secretory fate14-17. Cells of the secretory lineage include goblet, 
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enteroendocrine, and tuft cells found on the villi and Paneth cells found at the base of the 
crypt. Goblet cells secrete mucins to coat and protect the epithelium from the luminal 
contents and microbiota and are identified by their expression of mucin genes, including 
mucin 2 (Muc2)18. Enteroendocrine cells comprise approximately 1% of intestinal 
epithelial cells and secrete hormones that regulate digestion19. Although enteroendocrine 
cells include more than 10 different cell types producing distinct hormones, they can be 
identified by their general expression of chromagranin A (ChgA) and Synaptophysin20. 
Finally, the rare tuft cell is thought to play an essential role in the initiation of Type 2 
immune responses to helminth infections and is identified by expression of doublecortin 
and calcium/calmodulin-dependent protein kinase-like-1 (Dcamkl1)21,22. 
Paneth cells are of the secretory lineage, but remain at the crypt base intercalated 
between ISCs. Each crypt contains approximately 15 ISCs and 10 Paneth cells23. 
Compared to other differentiated cells types, Paneth cells are long-lived with a life-span 
of approximately 60 days24. Paneth cells have long been known to secrete antimicrobial 
peptides for protection from luminal microbes and are identified by expression of 
antimicrobials including Lysozyme and cryptidins23,25. A more recently established role 
for Paneth cells is the secretion of growth factors, including epidermal growth factor 
(EGF), wingless-type MMTV integration site family, member 3A (Wnt3a) and Notch 
ligands26 to support ISC maintenance and proliferation. 
 
Intestinal Stem Cells: Identification and Maintenance 
 ISCs reside at the base of the crypt and drive constant regeneration of the intestinal 
epithelium, with epithelial turnover occurring every 3-5 days7. Two distinct ISC types been 
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identified, with varying proliferative capacities. Traditionally, ISCs were termed “crypt-
based-columnar” cells in reference to their position at the crypt base intercalated among 
Paneth cells. These “actively cycling” ISCs (aISCs) divide approximately once every 24 
hours4, give rise to TA progenitor cells, and maintain the day to day epithelial turnover 
during homeostasis. In contrast, facultative or “reserve” ISCs (rISC) found in the ‘+4 
position’ (4 cell positions up from the base of the crypt) are slowly cycling or quiescent 
during homeostasis27 and only become activated following intestinal damage28. These 
rISCs have historically been described as “label-retaining” cells based on their functional 
capacity to retain expression of DNA-labeling agents29. Their capacity for activation and 
renewal in response to injury has made rISCs the focus of many recent studies7,30. This 
dissertation will focus only on regulation of the aISC population by extrinsic factors, so 
from here on aISCs will be referred to simply as ISCs. 
 Biomarkers that enable isolation of live ISCs have only recently been identified. 
The first ISC biomarker identified was the leucine-rich-repeat-containing G protein 
coupled receptor 5 (Lgr5)31.  By linking Lgr5 expression with EGFP protein expression in 
vivo, the Lgr5EGFPiresCreERT2 knock-in mouse model (from here on to be referred to 
as Lgr5-EGFP) allowed for Lgr5-GFP+ ISCs to be directly visualized in the intestinal 
crypt31. By crossing the Lgr5-EGFP mouse with a Rosa26LacZ reporter mouse, 
administration of Tamoxifen allowed the inducible CreERT2 to recombine floxed alleles 
to permanently label Lgr5-expressing cells and all their progeny32. These early lineage 
tracing studies demonstrated that the Lgr5+ ISC marked aISCs that were able to give rise 
to all other epithelial cell lineages in vivo31. Deletion of Lgr5 has little effect on crypt 
proliferation; however, mutation of leucine-rich-repeat-containing G protein coupled 
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receptor 4 (Lgr4), which is also found in intestinal crypt cells, greatly decreases crypt 
epithelial cell proliferation33. Most prominently, knockout both of Lgr4 and Lgr5 entirely 
stops crypt proliferation34. LGR4 and LGR5 promote Wnt signaling34, suggesting the 
strong dependence of ISC function on the Wnt signaling pathway. 
Wnt signaling is integral in many tissues to promote proliferation35 and is found in 
a gradient along the crypt 36,37. Expression of specific Wnts (mice have 19 of them) is 
regional along the crypt-villus axis, with epithelial-derived Wnts being found in a gradient 
that is highest at the base of the crypt and decreases moving towards the villus36,37. To 
briefly summarize relevant canonical Wnt signaling, in the absence of receptor activation, 
cytoplasmic β-catenin (catenin (cadherin associated protein) beta 1, Ctnnb1) is destroyed 
by the APC destruction complex. To activate Wnt signaling, Wnt proteins bind to the 
cysteine-rich domain of Frizzled-Lrp5/6 receptors and dephosphorylates the APC 
destruction complex, rendering it incapable of interacting with β-catenin. This allows β-
catenin to accumulate within the cell, travel to the nucleus, and bind to TCF/LEF proteins 
to regulate expression of Wnt target genes including myelocytomatosis oncogene (Myc), 
cyclin D1 (Ccnd1), CD44 antigen (Cd44), and axin 2 (Axin2)38. In mice, loss of TCF3 
causes loss of proliferative crypts39 and loss of β-catenin causes loss of ISC markers, 
terminal differentiation of epithelium and ultimately a fatal loss of intestinal function40, 
highlighting the importance of Wnt signaling for ISC proliferation.  
Since the discovery of Lgr5 as an ISC biomarker, additional biomarkers that are 
also Wnt target genes, including SRY (sex determining region Y)-box 9 (Sox9)41, achaete-
scute family bHLH transcription factor 2 (Ascl2)42, and olfactomedin 4 (Olfm4)43,44 have 
been identified. The transcription factor Sox9 is a Wnt target gene and has been shown 
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to regulate ISC proliferation45,46. Not only was Sox9 found to be an ISC marker, it also 
marked all proliferating cell types in the crypt at various expression levels: at high levels 
in rISCs and enteroendocrine cells, low levels in aISCs, and sublow levels in TA 
progenitor cells41,47. The ability to isolate ISCs and other crypt epithelial cells by 
expression of enhanced green fluorescent protein (EGFP) driven by a Sox9 promoter has 
allowed for the development of elegant, high-throughput studies of ISCs in vitro48.  
In order for ISCs to maintain their proliferative capacity and an appropriate ratio of 
ISC renewal versus differentiation, a delicate balance of growth factor signaling is 
required. Gradients of Wnts and bone morphogenic proteins (BMPs) have been found to 
be inversely related and influence proliferative capacity as cells migrate away from the 
crypt base36,37,49. In contrast to Wnt signaling, BMP signaling restricts stemness and 
proliferation. Binding of BMPs to their receptors leads to phosphorylation and activation 
of receptor-regulated SMAD family members (SMAD) 1, 5, and 8 (Smad1, Smad5, and 
Smad8) to form complexes with Smad4 and regulate gene expression in the nucleus50. 
In the intestine, BMP2 and BMP4 is secreted by intra-villus and inter-crypt mesenchymal 
cells,51 whereas the BMP antagonists noggin (Nog) and gremlin 1 (Grem1) are mainly 
expressed in mesenchymal cells beneath the crypt49, resulting in a gradient of BMP 
activity along the crypt-villus axis. BMP signaling is required for intestinal homeostasis, 
as BMP inhibition causes abnormal villus morphogenesis, epithelial hyperplasia, and 
ectopic crypt formation52. Recently, BMP has been shown to limit ISC self-renewal and 
decrease expression of the ISC genes Lgr5, Olfm4, and Ascl2 via Smad53. In conjunction 
with ISC biomarker identification, the identification of epithelial and mesenchymal growth 
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factors required for ISC maintenance have allowed for the development of in vitro ISC 
culture methods. 
 
Studying Intestinal Stem Cells in vitro: Organoid Culture System 
The ability to culture ISCs has only been developed in the last ten years after the 
isolation of single LGR5+ ISCs. When grown in an ECM-rich culture substrate, single 
ISCs and crypts form into 3-dimensional structures54. When initial culture conditions were 
established in 2009, resulting self-organizing crypt-villus structures (or “mini-guts”) that 
formed from single Lgr5+ ISCs were termed “organoids”32,54. Additionally, 3-dimensional 
structures resulting from human pluripotent ISCs that are differentiated into intestinal 
tissue in vitro were also termed “organoids”55. However, debate has been had on the 
proper nomenclature of these in vitro structures. In 2012, members of the NIH Intestinal 
Stem Cell Consortium proposed a systematic nomenclature to more specifically describe 
the 3-dimensional structures based on source tissue and cell types present56. Multi-lobed 
structures that develop from isolated intestinal epithelial cells are referred to as 
“enteroids” (isolated from the small intestine) or “colonoids” (isolated from the colon), 
whereas an the term “organoid” refers to a multicellular cluster of epithelial and 
mesenchymal elements56. Both “organoids” and “enteroids” are regularly used to define 
3-dimensional structures that arise from isolated epithelial cells from the small intestine; 
therefore, they will here on be referred to as “organoids.”  
Growth factors that recapitulate the factors observed in the ISC niche in vivo are 
required for ISC maintenance and expansion in vitro. When culturing isolated crypts that 
contain ISCs and Paneth cells (Figure 1.2A), exogenous Wnt is not required since it is 
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supplied by Paneth cells. However, EGF, R-Spondin, and Noggin are required for ISC 
survival32. EGF drives Mitogen-activated protein kinases (MAPK) signaling to inhibit 
epithelial cell shedding and extrusion57,58, R-Spondin, a Wnt agonist, further activates the 
Wnt pathway59, and Noggin inhibits BMP signaling allowing ISCs to remain 
undifferentiated51,52. When single ISCs are cultured, no source of Wnt is present; 
therefore, exogenous Wnt is also needed to support isolated ISC growth. Recent creation 
of cell lines that create R-spondin, Wnt, and Noggin conditioned media have reduced the 
cost of growth factors for in vitro organoid cultures60. 
Manipulation of key signaling pathways has been shown to increase the survival 
of ISCs in vitro. Addition of CHIR99021, a glycogen synthase kinase 3β inhibitor that 
enhances Wnt signaling61, promotes proliferation of ISCs62. Furthermore, addition of 
Valproic acid, a histone deacetylase inhibitor that activates Notch signaling63,64, and 
CHIR99021 resulted in nearly homogenous cultures of ISCs in organoids62. Importantly, 
a 100-fold increase was observed in the survival of single ISCs when cultured with 
CHIR99021 and Valproic acid62, suggesting the need for niche cell-derived growth factors 
for enhanced ISC survival in vitro.  
 An essential requirement for the survival of ISCs ex vivo and culture of ISCs in 
vitro is an ECM substrate due to the requirement of integrin binding65. Traditionally, ISCs 
have been grown in either Type I Collagen66 or Matrigel32, a basement membrane 
preparation from an Engelbreth-Holm-Swarm mouse sarcoma. Recent development of 
tunable synthetic matrices has allowed for the use of defined ECM to finely regulate the 
ISC expansion and organoid formation67. Enrichment of hydrogels supplemented with key 
ECM components found within the ISC niche in vivo, including fibronectin, laminin, 
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collagen IV, hyaluronic acid and perlecan, have also been shown to further enhance ISC 
survival and proliferation67. 
Organoids accurately recapitulate the architecture of native intestine with 
proliferative crypt-like buds and zones of differentiated cells (Figure 1.2B)68. The crypt-
like buds contain Lgr5+ ISCs intercalated among Paneth cells located at the bud base. 
ISCs give rise to TA progenitors that differentiate as they migrate out of the bud into an 
inter-villus domain where they form all of the cell types found in vivo32. Differentiated cells 
ultimately undergo anoikis and slough off into the organoid lumen, mimicking the 
physiological turnover of the epithelium in vivo. Organoids grow to have many buds, and 
thus expanding the number of ISCs per organoid. Organoids can also be dissociated into 
crypt bud units or to single cells and expanded indefinitely in vitro32. Although culture 
conditions are able recapitulate the essential factors to support ISCs, the niche 
environment that provides these factors in vivo is dynamic depending on the physiologic 
state of the intestine. 
 
Components of the Intestinal Stem Cell Niche 
The ISC niche niche environment is made up of both cellular and non-cellular 
components (Figure 1.3). Cells in the niche are in close proximity to ISCs and include 
epithelial Paneth cells that are intercalated between ISCs, subepithelial pericryptal 
myofibroblasts that encapsule the crypt, and immune cell types that vary depending on 
the state of intestinal inflammation. All of these cells interact with and are supported by 
the non-cellular extracellular matrix (ECM), which provides a biological scaffold for cellular 
interaction. 
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The two main cellular components of the niche, the Paneth cells and the pericryptal 
myofibroblasts, secrete various mitogens and morphogens, including Wnts, the Notch 
ligand Delta-like 1 (DLL1), EGF, and Noggin, that regulate ISC survival and function7. 
Genetic ablation of Paneth cells does not critically impair epithelial function in the mouse 
intestine suggesting a functional overlap of cellular roles within the niche69,70, with the 
likely candidate being the subepithelial myofibroblast. A heterogenous population of 
myofibroblasts exists throughout the lamina propria71; however, pericryptal 
myofibroblasts, which are intimately associated with the ISCs in vivo secrete secrete Wnt 
proteins72,73, supplying a non-epithelial source of Wnt to drive epithelial regeneration. 
When ISCs are cultured in vitro, co-culture with subepithelial myofibroblasts enhances 
ISC survival and organoid size and removes the need for exogenous Wnt agonists73. 
Myofibroblasts have also been found to secrete other cytokines, growth factors, and 
essential ECM proteins for ISC survival and maintenace71. 
Supporting the ISC niche, a physical scaffold of ECM is in contact with all the 
cellular components (Figure 1.3)74. The ECM is secreted by resident niche cells to provide 
support for and influence neighboring cells75. Both epithelial and mesenchymal 
compartments contribute to ECM in the niche76; however, specific ECM contributions of 
individual cell types have not been determined. The basolateral membrane of epithelial 
cells lies directly on the basement membrane, a thin sheet of ECM composed mostly of 
laminins and collagen IV and interacts with epithelial cells through integrin binding74. This 
basement membrane also physically separates the epithelium from pericryptal 
myofibroblasts and other cells residing in the lamina propria74. ECM is also found 
throughout the lamina propria supporting other cell types including fibroblasts, blood 
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vessels, and neurons. In general, this more diffuse ECM is composed of an intertwining 
mix of glycosaminoglycans and proteins, including collagens, laminins, elastin, and 
fibronectin, found in 3-dimensional patterns and gradients75. While studies in other 
tissues, like mammary gland77 and bladder78, establish a role for ECM in stem cell niches, 
the influence of ECM on ISCs is still being defined2. 
ECM can impact cell behavior by modulating signaling pathways that control cell 
proliferation, growth, and death by serving as a substrate to physically anchor cells, 
providing biomechanical stiffness, and creating reservoirs of soluble factors75,79. 
Anchorage to ECM is essential for ISC survival, as intestinal epithelial cells undergo 
apoptosis without an ECM substrate for epithelial beta 1 integrins to interact with65. 
Stiffness of the surrounding ECM has also been found to direct ISC fate, with a high matrix 
stiffness of a synthetic scaffold enhancing ISC expansion and a low matrix stiffness 
supporting ISC differentiation67. 
The role of ECM as a reservoir for soluble factors has not been studied in the 
context of the intestinal crypt; however, gradients of growth factors, including Wnt and 
BMP, exist along the crypt-villus axis. Heparan sulfate proteoglycans, found on many 
ECM proteins, can help to form gradients by stabilizing growth factors such as Wnt and 
preventing protein aggregation80,81. In the intestine, mice broadly lacking heparan sulfate 
proteoglycans have reduced expression of Wnt target genes during crypt regeneration 
after irradiation80. ECM proteins with attached heparin sulfate proteoglycans, such as 
Collagen XVIII (Col18a1), are found in the basement membrane in the ISC niche and 
potentially play a critical a role in niche dynamics82. Other basement membrane proteins, 
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including laminins, are regionally distributed along the crypt villus axis74, suggesting a 
relationship between regional ECM composition and epithelial cell function.  
 
Immune Cell Components of the Small Intestine 
The cellular and ECM components of the ISC niche remain relatively constant 
throughout the homeostatic life of the animal; however, immune system components 
dynamically interact with niche cells depending on tissue damage and inflammation83,84. 
The immune system in the intestine is the largest compartment of the immune system in 
the body, as it is constantly exposed to antigens from the diet and microbiota found in the 
intestinal lumen10. Regional differences in intestinal immunity are prominent, as the 
luminal microbial load and the amount immune cell tissue increases from proximal to 
distal small intestine10. The majority of immune cells are located in the lamina propria 
either individually scattered or in organized lymphoid structures collectively termed gut-
associated lymphoid tissue (GALT)10.  
Two types of GALT exist: larger Peyer’s patches and smaller lymphoid aggregates 
collectively termed solitary isolated lymphoid tissue (SILTs)10. Peyer’s patches are large 
aggregates of B cell lymphoid cells that are macroscopic85. B cells present antigens and 
secrete antibodies and cytokines86. Peyer’s patches have germinal centers, which contain 
active B cells, suggesting continual immune stimulation by luminal antigens10,85. 
Intercalated among B cell aggregates are smaller areas of T cells10. T cells can bind to 
antigen-presenting B cells to cause further antibody secretion, as well as to other antigen-
presenting cells, including dendritic cells and macrophages, and secrete cytokines to 
cause inflammation87. Peyer’s patches increase in size, density and number from the 
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duodenum to the ileum as the microbial burden in the intestinal lumen increases, with 
approximately 100-200 in humans88 and 6-12 in mice85. Like Peyer’s patches, SILTs 
contain a germinal center and B cells, but no clear T cell zone89 and are smaller10. 
Throughout the small intestine, mice have up to 1,500 SILTs and humans have more than 
30,000 SILTs90,91. SILTS include cryptopatches and isolated lymphoid follicles (ILFs) that 
are found more interspersed throughout the lamina propria10. These aggregates range in 
size dependent upon their maturity, as cryptopatches mature into ILFs with age and 
bacterial burden90. The human ileum has the highest concentration of ILFs, with one ILF 
for every 28 villi, due to increased microbial presence92.  
 In addition to aggregates of immune cells, individual T and B cells are found 
throughout the lamina propria and have been extensively researched due to their 
definitive roles in both intestinal homeostasis and disease10. Innate lymphoid cells (ILCs) 
are a relatively newly identified subset of immune cells that are unique in they lack 
antigen-specific receptors, unlike the T and B cells, and are thought to play a large role 
in the immune defense at mucosal surfaces93. ILCs can be categorized based on their 
cytokine production into three main groups, termed ILC1, ILC2 and ILC3s. Group 1 ILCs 
are primarily involved in intracellular pathogens, viruses and tumors, Group 2 ILCs are 
primarily involved in protecting again helminth invasion, wound healing, and allergic 
responses, and Group 3 ILCs are primarily involved in resistance to bacterial and fungal 
infections93,94. Importantly, ILCs participate in cytokine and chemokine signaling, and can 
impact epithelial cells to promote regeneration and repair95,96. 
Although the intestinal immune system is vast, the intestinal epithelium has 
protective abilities that allow it to act as the primary line of defense against luminal 
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microbiota before antigens interact with underlying immune cells. Goblet cells secrete 
mucins to form a strong mucus barrier extending 150μM above the epithelium, with a 
loose outer layer to immobilize bacteria and a firm inner layer devoid of bacteria to protect 
the epitheluim97. Paneth cells can directly sense microbiota and regulate production of 
antimicrobials and defensins98. Additionally, epithelial cells themselves can secrete pro-
inflammatory cytokines to elicit an immune response99. Although these defenses limit 
barrier breaching by luminal bacteria and pathogens, invasion does occur and 
subsequently faces both a strong adaptive and innate immune response from the 
intestine10. Immune sensors, including dendritic cells and macrophages, respond to broad 
stimuli found in the intestinal lumen. Dendritic cells, found mostly in SILT, can directly 
sense intestinal contents by extending their dendritic processes into the intestinal 
lumen100. Dendritic cells and macrophages in the lamina propria respond to intestinal 
antigens by activating T cells and promoting activation of other lymphoid cells101,102. 
Depending upon the antigen sensed, dendritic cells and macrophages can also secrete 
cytokines to influence lymphoid and epithelial cell responses103,104. Failure of the immune 
response towards invading bacteria and pathogens can result in chronic inflammation and 
intestinal disorders and diseases, including malabsorption, enteritis, diarrhea, 
inflammatory bowel disease, and cancer. 
 
Intestinal Mucosal Response to Inflammation and Healing 
Chronic inflammation of the intestine can result in loss of the epithelium and 
impaired epithelial regeneration, producing painful lesions that are unable resolve. An 
impaired epithelial barrier allows for the constant infiltration of luminal bacteria and 
pathogens into the lamina propria, resulting in the inability for the intestine to fully heal. 
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Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the intestine that 
effects over 1 million patients in the United States and recent epidemiologic studies 
suggest the incidence is expected to exponentially increase over the next 10 years105. 
IBD is characterized into two main types: 1. Crohn’s disease, which can affect any part of 
the gastrointestinal tract in patches and extend throughout all intestinal layers, and 2. 
Ulcerative colitis, which only affects the innermost layer of colon and rectum in continuous 
fashion83. The mechanisms of IBD etiology remain largely unknown; however, leading 
hypotheses suggest that disease results from a dynamic mix of genetic, immunological, 
and genetic risk factors106. For the purpose of this dissertation that concentrates on the 
small intestine, Crohn’s disease will be the focus from here on as 65% of Crohn’s disease 
patients have ileal involvement107.  
Crohn’s disease features an exaggerated immune response, impaired barrier 
function, and progressive microbial product invasion107,108. These factors fuel chronic 
inflammation, which leads to lifelong disease even with therapy. However, the natural 
course of Crohn’s disease has unpredictable periods of remission, where disease 
symptoms are minimal, and relapse (or “flares”), where inflammation and disease 
symptoms are present109. Overall, 20% of Crohn’s disease patients have relapses of 
disease every year and 67% of patients have relapses within the first eight years post-
diagnosis110. The damage and repair that results from cycles of relapse and remission 
make it challenging for the epithelium to regenerate and allow the wound to completely 
heal.  
Epithelial response to damage is a two-step process. First, during the repair 
process after injury, the epithelium adjacent to the injury undergoes restitution, where 
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epithelial cells migrate over the damaged area to reconstitute the epithelial barrier111. This 
redistribution of cells is rapid, does not require epithelial proliferation, and is regulated by 
cytokines112. After epithelial restitution, epithelial cells begin to proliferate to increase the 
pool of epithelial cells that can reconstitute the epithelial barrier111. During this phase, 
crypts become elongated as more undifferentiated cells proliferate to increase the total 
epithelial cell number111,113. Additionally, crypt fission, or the division of one crypt into two 
crypts, may occur to also increase the available pool of proliferating cells113. Finally, 
differentiation of epithelial cells occurs to re-form the epithelium and create all of the 
differentiated cell lineages to reconstitute the homeostatic epithelial barrier111. A 
prognostic factor of long-term IBD remission is mucosal healing, as compared to 
improvement in clinical symptoms109,114, suggesting that complete mucosal healing or 
remission is the goal for IBD treatment. This goal of remission is not trivial as there are 
many components of the mucosa that interact in concert to maintain mucosal integrity. 
 Intestinal damage in Crohn’s disease is more than just epithelial damage and can 
be present in subepithelial tissue. In inflamed lesions, local immune cells secrete serine 
proteases and matrix metalloproteases to degrade ECM and allow for the influx of 
infiltrating immune cells and myofibroblasts115. However, when the inflammation 
subsides, the ECM and sub-epithelial tissue need to undergo wound healing to create a 
new environment for epithelial proliferation and differentiation. During the initial phases of 
wound healing and epithelial restitution, myofibroblasts migrate to the site of the lesion 
and proliferate by growth factors and cytokines secreted from platelets, inflammatory 
cells, and endothelium116. Fibroblasts and myofibroblasts then deposit ECM, mainly 
collagen and fibronectin. Depending on how large the wound is, myofibroblasts also 
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contract the wound to limit the area the epithelium has to cover115. As repair continues, 
neovascularization occurs, more ECM is synthesized, and the number of recruited 
immune and mesenchymal cells diminishes116. Finally, remodeling of the ECM is critical 
to support appropriate angiogenesis, innervation, immune cell response, and epithelial 
proliferation117.  
 Healing of the epithelium to restore barrier function is of utmost importance to limit 
microbial product invasion and restore the homeostatic immune response. In addition, 
epithelial goblet and Paneth cells are required to re-create the epithelial barrier118. 
Although it is known that ISCs are integral for damage-induced intestinal 
regeneration28,119, the mechanisms that regulate ISC function and induce epithelial 
regeneration are poorly understood. It has recently been shown that Interleukin-22 (IL22), 
a cytokine that is upregulated in IBD, promotes proliferation and expansion of ISCs in an 
in vitro organoid model as well as in mouse models of graft-versus-host disease and 
irradiation120,121. Eventual re-establishment of the crypt-villus architecture and 
proliferative cell gradient is also essential, as the physical crypt structure protects 
proliferating cells from microbial metabolites. For example, a microbial metabolite screen 
revealed that butyrate, a bacterial metabolite that is only exposed to ISCs and TA 
progenitors during injury, suppresses epithelial cell proliferation122.  
 In both homeostatic and regenerative states of the small intestine, extrinsic 
components of the ISC niche are integral for ISC survival and proliferation. This 
dissertation explores the role of two integral extrinsic components, the immune cells and 
the ECM, on their influence of ISC survival, proliferation and differentiation. First, the 
influence of Interleukin 22, which is upregulated in patients with IBD and secreted from 
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immune cells in close proximity to ISCs, is investigated using an in vitro model of ileal 
ISCs (Chapter 2). Methods developed and utilized for assessing intestinal epithelial 
differentiation and function in response to inflammation using the in vitro organoid culture 
model are outlined in a book chapter (Appendix A). Next, the influence of intestinal ECM 
is broadly investigated by creating acellular, porcine small intestinal ECM scaffolds and 
determining its capacity to support mouse ISCs (Chapter 3). Further understanding of 
how extrinsic factors, and particularly those in close contact with ISCs, can influence ISC 
function is of central importance when developing therapies for intestinal disease that 
affect more than just the ISCs themselves. Furthermore, understanding the dynamic 
communication and interaction between the ISCs and the supportive niche components 
will also establish key components needed for further developing intestinal tissue 
engineering strategies.  
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Figure 1.1. Small intestinal anatomy and epithelial cell lineages. (A) The small 
intestine has four main layers, with the innermost mucosa lined with a single layer of 
epithelial cells and organized into a villus-crypt architecture. (B) The small intestinal 
epithelium contains undifferentiated cells in the crypt, including ISCs and TA progenitor 
cells. TA progenitor cells differentiate into either absorptive or secretory cell types which 
form the five major differentiated cell types. 
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Figure 1.2. ISCs form organoids in vitro. (A) Isolated crypts contain ISCs, Paneth cells, 
and undifferentiated TA progenitor cells. (B) When cultured in vitro, isolated crypts and 
single ISCs form organoids that recapitulate the in vivo architecture zones of differentiated 
and proliferative cells.  
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Figure 1.3. The intestinal stem cell niche. In vivo, the intestinal epithelium resides on 
a basement membrane that creates a physical barrier between the epithelium and the 
underlying lamina propria. The ISC niche is comprised of Paneth cells in the epithelium 
and myofibroblasts and immune cells in the lamina propria, which are all in close proximity 
to ISCs.  
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CHAPTER 2: ELEVATED IL22 INHIBITS EPITHELIAL STEM CELL EXPANSION IN 
AN ILEAL ORGANOID MODEL1,2 
 
Overview 
Background & Aims: Crohn’s disease (CD) is an inflammatory bowel disease that 
affects the ileum and is associated with elevated cytokines. Though Interleukins (IL) IL6, 
IL17, IL21 and IL22 are elevated in CD and associated with disrupted epithelial 
regeneration, little is known about their effects on the intestinal stem cells (ISCs) that 
mediate tissue repair. We hypothesized ILs may target ISCs and reduce ISC-driven 
epithelial renewal. Methods: A screen of IL6, IL17, IL21 or IL22 was performed on ileal 
mouse organoids. Computational modeling was used to predict microenvironment 
cytokine concentrations. Organoid size, survival, proliferation, and differentiation were 
characterized by morphometrics, qRT-PCR, and immunostaining on whole organoids or 
isolated ISCs. ISC function was assayed using serial passaging to single cells followed 
by organoid quantification. Single-cell RNAseq was used to assess Il22ra1 expression 
patterns in ISCs and Transit-Amplifying (TA) progenitors. An IL22-trangenic mouse was 
used to confirm the impact of elevated IL22 levels on proliferative cells in vivo. Results:  
 
1This chapter has been resubmitted to Cellular and Molecular Gastroenterology and 
Hepatology. 
 
2Full list of contributing authors: Bailey Zwarycz, Adam D. Gracz, Kristina R. Rivera, Ian 
A. Williamson, Leigh A. Samsa, Josh Starmer, Michael A. Daniele, Luisa Salter-Sid, 
Qihong Zhao, Scott T. Magness 
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IL22 demonstrated decreased ileal organoid survival, however, resistant organoids grew 
larger and exhibited increased proliferation over controls. Il22ra1 was only expressed on 
a subset of ISCs and TA progenitors. IL22-treated ISCs did not exhibit appreciable 
differentiation defects, but ISC biomarker expression and ISC self-renewal-associated 
pathway activity was reduced by IL22 and was accompanied by an inhibition of ISC 
expansion. In vivo, chronically elevated IL22 levels, similar to predicted microenvironment 
levels, exhibited increases in proliferative cells in the TA progenitor zone with no increase 
in ISCs. Conclusions: Elevated IL22 limits ISC expansion in favor of increased TA 
progenitor cell expansion. 
 
Introduction 
 Inflammatory bowel disease (IBD) features exaggerated immune responses that 
can affect the small intestine (Crohn’s Disease) or colon (Ulcerative Colitis)123,124. Early 
initiation of inflammation is complex and influenced by a number of contributing factors 
such as underlying genetics and composition of the gut microbiota; but ultimately, it is 
chronic inflammation-driven breaches in the epithelial barrier that fuel the continuous 
cycle of inflammation and impaired epithelial regeneration that culminates in clinical 
sequelae, such as ulcerated regions of submucosa, pain, and bleeding1,3. Intestinal 
epithelial stem cells (ISCs) typically regenerate the epithelial lining in a tightly coordinated 
balance between ISC self-renewal and differentiation into transit-amplifying (TA) 
progenitor cells and their post-mitotic descendants. How the inflammatory 
microenvironment in the ISC zone impacts this stereotypical process is poorly 
understood. 
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 Local immune cells in the gut secrete a wide array of cytokines that mediate 
initiation, progression, and resolution of inflammation in the small intestine and colon. 
During an inflammatory response, T cells and innate lymphoid cells (ILCs) secrete a 
subset of the cytokines called interleukins (ILs) into the ISC microenvironment112. 
Dysregulated cytokine responses are associated with IBD and are often characterized by 
chronically elevated serum levels of IL6, IL17, IL21 and IL22 and their associated 
signaling pathways112. For instance, in healthy individuals serum IL22 levels are reported 
at ~2pg/mL, while in Crohn’s Disease patients those levels are ~12-times higher at ~24 
pg/mL125. Importantly, these values represent systemic IL22 levels, which may not 
accurately reflect actual concentrations and the phenotypic consequences close to the 
mucosal inflammation site. This concept is particularly highlighted in the case of IL23, 
which at low concentrations promotes proliferation of human lung cancer cells, but inhibits 
proliferation and at high concentrations126. In the case of IBD, it is logical that IL 
concentrations would be considerably higher in the mucosal microenvironment, where 
the cytokine is produced by ILCs, and systemic levels would be effectively reduced by 
systemic diffusion and first pass removal by the liver. While empirical measurements of 
IL levels in the microenvironment are currently beyond the limits of technology, prediction 
of microenvironment levels may guide more physiologically relevant dose-response 
experiments in vitro and provide more accurate interpretations related to the mechanisms 
of action of ILs in the microenviroment. 
 In this study120, we use an Ileal organoid model to screen the impact that a subset 
of IBD-related ILs have on ISCs. Like a recent study, our screen revealed that IL22 has 
a profound influence on organoid size and survival in a concentration dependent manner, 
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and confirms that IL22 regulates epithelial proliferation and differentiation. Our study 
extends this prior work to model and investigate the role of IL22 in the ISC 
microenvironment, and importantly, draws a distinction between systemic levels of IL22 
reported in serum from IBD patients and predicted IL22 concentrations in the ISC 
microenvironment. Our study offers an alternative interpretation as to how elevated levels 
of IL22 in the microenvironment affect proliferative epithelial populations in the crypt.  
 
Results 
Screening IBD-related cytokines using an ileal organoid model. 
 Crohn’s disease, an IBD, is typically restricted to the ileum in the small intestine. 
We sought to test the impact of a number of IBD-related cytokines specifically on the ileal 
epithelium and observe the effects on ISCs in vitro. To do this, we used an ileal organoid 
model in which organoids were derived specifically from the terminal mouse ileum, a 
region that is involved in a majority of patients with Crohn’s disease. Intestinal organoids, 
also known as enteroids56, are spherical, ISC-driven epithelial structures that form in vitro 
when single ISCs or crypts are suspended in extracellular matrix and supplemented with 
defined growth factors that mimic the in vivo stem cell niche54. Organoids are comprised 
of ISCs that differentiate into all the epithelial absorptive and secretory lineages found in 
vivo and self-pattern with crypt buds containing ISCs that differentiate and migrate into 
intervening villus-like zones54. Because of these physiologically relevant properties and 
functions, organoids represent an excellent model to study the dynamics of ISC-driven 
regeneration in vitro.  
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 Organoids can be used as a rapid and easy screen to visually detect changes in 
properties that are regulated by ISCs, including growth and longterm self-renewal. We 
used this ileal organoid model system to test whether a subset of Crohn’s disease-related 
ILs would decrease ISC activity using organoid survival as a proxy for ISC survival and 
organoid size as a measure of ISC proliferation. IL16, IL1b, and TNFa levels in patients 
with IBD average about 100 pM (1,500 pg/mL), a concentration that was used to screen 
for IL effects on the ileal organoid epithelium127. Ileal crypts were allowed to establish in 
vitro for 1 day, then supplemented with 100 pM IL6, IL17, IL21, or IL22 for 6 days (Figure 
1A). While there was no significant size increase caused by IL6, IL17, and IL21, organoids 
treated with 100 pM IL22 grew approximately 3 times larger (Figure 1B,C). IL6, IL17, and 
IL21 had no significant effect on organoid survival, but IL22 caused an ~72% decrease in 
organoid survival compared to controls (Figure 1D). In this case, organoid survival is 
defined by organoid forming efficiency (OFE), which is number of organoids that derive 
from a single ileal crypt. Although there may have been more subtle effects of IL6, IL17, 
and IL21 on ISCs, we focused on investigating how IL22 affected ISC self-renewal and 
differentiation based on the overt organoid growth and death phenotype observed in the 
screen. 
 
IL22 imparts concentration-dependent effects on ileal organoids 
 IL22-dependent changes in organoid size and survival have been reported in 
organoids derived from a mixture of crypts isolated from full-length intestine120. It remains 
to be determined whether IL22 affects ileal specific epithelium in the same way. A dose-
response experiment demonstrated that 20 pM of IL22 was the lowest dose that caused 
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a significant increase in organoid size (Figure 1E). Organoid size continued to increase 
in a dose-dependent manner at each tested concentration up to 500pM (Figure 1E). 
Interestingly, while ileal organoid size increased as a function of IL22 concentrations, 
there was a decrease in OFE from crypts cultured in increasing concentrations of IL22 
(up to 500pM) (Figure 1E).  
Next we tested whether a reduction in OFE persisted over time. OFE was 
quantified in ileal organoid cultures exposed to two different IL22 doses: 60pM, a lower 
dose (60 pM) reported to cause increased organoid size but no decrease in OFE120, and 
500 pM, a higher dose demonstrated to cause both increased organoid size and 
decreased OFE (Figure 1F). There was a clear decrease in the ability of crypts to 
generate organoids at both concentrations and this trend persisted over the two-week 
time course (Figure 1F). To determine whether these effects were IL22 dependent, ileal 
organoids were treated with the higher IL22 concentration (500 pM) in the presence or 
absence of an IL22-neutralizing antibody (Figure 1G,H). The neutralizing antibody 
blocked IL22-dependent phosphorylation of STAT3128, a key downstream signaling 
mediator of IL22 (Figure 1G). Importantly, the IL22 neutralizing antibody blocked size 
increases in IL22-treated ileal organoids demonstrating the phenotype was IL22-
dependent (Figure 1H). While one study that lower levels of IL22 does not impart a 
negative effect on organoids derived from a mixture of crypts derived from full-length 
intestine120, our results demonstrate a significant decrease in ileal OFE at both 
concentrations. Interestingly, while IL22 impaired organoid formation from some ileal 
crypts, the crypts that survived grew bigger and developed faster than untreated controls 
crypts.  
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IL22-receptor is only expressed in subsets of intestinal epithelial ISCs and TA 
progenitors 
The heterogeneous response of some crypts to elevated IL22 levels suggested 
ISCs in the base of each crypt might have differential responses to elevated IL22. IL22 
signals through the receptor IL22RA1 and activates STAT3 signaling128, so we reasoned 
that ISCs might have variable responses to IL22 based on differential expression of its 
cognate receptor. To test this, the ileal epithelium was dissociated to single cells and 
populations were differentially FACS-enriched for ISCs, TA progenitors, 
enteroendocrine/tuft cells, Paneth cells, and Goblet/absorptive cells based on established 
methods using a Sox9EGFP mouse model41. Across these populations, Il22ra1 mRNA 
was detected at the highest levels in the TA progenitor cells, but was also detected in 
each of the other populations, albeit at significantly lower levels (Figure 2A).  We next 
investigated Il22ra1 mRNA expression at cellular resolution using single-cell RNA-
sequencing. A previously published dataset that surveyed the full transcriptome of 1,522 
single mouse small intestinal cells was interrogated to define the extent 
of Il22ra1 expression heterogeneity different lineages (Figure 2B-E). Expression of 
Il22ra1 mRNA was quantified in a binary ‘on/off’ manner for each ISC, progenitor, and 
differentiated cell population (Figure 2B). Expression of Il22ra1 was observed only in 
subsets in each population, and moreover, in those cells that expressed Il22ra1, there 
was a broad range of expression levels (Figure 2C).  A higher resolution view of just the 
ISC and TA progenitor cells further highlights the heterogeneous expression patterns of 
Il22ra1 in these populations (Figure 2D,E).  We did not observe distinct clustering 
of Il22ra1-positive or Il22ra1-negative cells in the t-SNE clustering analysis, suggesting 
 30 
that while Il22ra1 expression is heterogeneous, it does not identify discrete sub-
populations of ISCs or TA progenitors based on this type of analysis (Figure 2C-E). These 
data suggest that during homeostasis, only a subset of ISCs and TA progenitor cells are 
receptive to IL22 stimulation. 
 To determine if the heterogeneous Il22ra1 expression extended to the protein 
level, we immunostained ileal tissue sections to assess IL22RA1 localization, and 
quantified the number of IL22RA1-expressing cells by flow cytometry (Figure 2F,G). 
Immunostaining demonstrated broad expression of IL22RA1 in crypt-based epithelial 
cells with higher levels apparent in the TA progenitor zone120 (Figure 2F). Flow cytometry 
confirmed at the protein level that only sub-populations of epithelial cells express the IL22 
receptor (Figure 2G). We attempted to test functional differences between ILR22A1+ and 
ILR22A1- by FACS-isolation and OFE assays on single ISCs; however, all commercially 
available antibodies detect cytoplasmic epitopes and were not suitable for isolation of live 
cells. While technical limitations preclude testing functional differences in ILR22A1+ and 
ILR22A1- ISCs, the heterogeneous expression of IL22RA1 in ISC and TA progenitors 
suggest there are mechanistic differences that could impact ISC behavior during an 
inflammatory response in vivo.  
 
Computational modeling predicts higher levels in the ISC microenvironment than 
in serum 
A fundamental question in studies investigating the role of ILs in IBD pathogenesis 
is, what are the physiologically relevant IL concentrations that contribute to the disease? 
IL22 levels reported for IBD patients are based on peripheral blood serum levels125, which 
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likely do not accurately reflect the IL22 levels at the site of secretion in the intestinal or 
colonic mucosa. Currently, there is no accurate method to measure absolute levels of 
IL22 in the ISC microenvironment, which we define as the distance of IL22-secreting 
lymphocytes (ILC3s) from the crypt base (~6-17 µm; Figure 3A). Therefore, we used 
COMSOL MultiphysicsÒ  to computationally model and predict IL22 concentrations that 
ISCs might experience in their microenvironment during an inflammatory episode.  
Empirically derived values for factors that could influence IL22 concentrations, 
such as IL22 secretion rates from ILC3s, distances of ILC3s to ISC, number of ILC3s in 
a lymphoid follicle, distance of lymphoid follicle to ISCs, and radius of ILC3s were applied 
to the model (Figure 3A). Previous work established that isolated and induced ILCs can 
secrete IL22 in culture129, and from this study, we calculated that a single ILC can secrete 
IL22 at an average rate of 4 fg/hr. An estimated diffusion coefficient for IL22 was based 
on its molecular weight130-132. IL22-secreting ILC3s express RORgt133, which was used as 
marker to measure the distances of  ILC3s to the ISCs in the base of the crypt. ILC3s are 
as close as 6 μM from the base of the crypt (Avg distance ~6.0 μm; Figure 3A). ILC3s 
also exist in the mucosal microenvironment localized to innate lymphoid follicles10, which 
were measured to be as close as 17 μm from the crypt base (Avg distance ~17 µm; Figure 
3A). These data demonstrate that cells expressing IL22 can be in very close proximity 
(on the single cell diameter scale) to the ISC zone.  
Using these parameters, we first asked how long it would take for a single ILC3 
cell to secrete enough IL22 to achieve a concentration of 500 pM at the ISC zone (Figure 
3B). The model predicts that IL22 can accumulate to 500 pM within a distance of 0-9 µm 
within 4 minutes (Figure 3B). In the setting of Crohn’s disease and chronic inflammation, 
 32 
IL22 is upregulated and an influx of IL22-secreting ILC3s is observed134; therefore, it is 
expected that the single-ILC3 model is a conservative estimate and likely under-
represents concentrations of IL22 in the inflammatory microenvironment. Since ILC3s 
also exist in innate lymphoid follicles10, we next modeled IL22 microenvironment 
concentrations up to 21 μm, which includes the average distance of a lymphoid follicle 
from the ISC zone (Figure 3C). We also used secretion values for 67 ILCs, which is the 
average number of ILC3s in a cross section of a lymphoid follicle (Figure 3A). While the 
model only takes into consideration the IL22 secretion from the number of ILC3s in a 2-
dimensional space, the model effectively approximates the microenvironment 
concentrations in 3-dimensional space.  Using the follicle model prediction, ISC cells in 
close proximity to the follicle (0-21 μm) would detect 500 pM IL22 within 11 seconds of 
initiation of secretion (Figure 3C). Although the IL22 concentrations are modeled in a 
closed system and the rates of IL22 removal and degradation are unknown, the 
computational models suggest the 500 pM IL22 concentration used in the ileal organoid 
model are not unreasonable to achieve in the ISC/ILC3 inflammatory microenvironment, 
therefore this IL22 concentration was used throughout the remainder of the study. 
 
IL22 does not cause appreciable lineage bias of ISCs  
While 500 pM of IL22 has a clear impact on ileal organoid survival and size, these 
metrics do not reflect IL22-dependent influences directly on ISC differentiation. Aberrant 
differentiation of ISCs caused by elevated levels of IL22 could explain a loss of ISC self-
renewal and regenerative capacity of the gut epithelium in inflammatory conditions. We 
performed a study using isolated ISCs to test whether elevated IL22 influenced early 
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differentiation programs directly on ISCs. ISCs were FACS-isolated and incubated with 
500 pM IL22 for 6 hours followed by gene expression analysis for lineage restricted 
biomarkers: absorptive enterocyte (SI, Sucrose Isomaltase), Paneth (Lyz2, Lysozyme2), 
goblet, (Muc2, Mucin2), and enteroendocrine (ChgA, Chromogranin A) (Figure 4A). In 
these studies only lysozyme mRNA, which is associated with Paneth cell lineage, was 
significantly increased. To determine the impact of elevated IL22 on the tissue level, we 
tested ileal organoids treated with 500 pM IL22 for expression of all key genes that mark 
the main differentiated cell types. In this case, elevated IL22 concentrations led to 
reduced or unchanged levels of all genes except for the Paneth cell biomarker, Lyz2 
(Figure 4B). To determine whether this increase in lysozyme mRNA was associated with 
increased Paneth cells, IL22-treated ileal organoids were immunostained for Lysozyme 
and Paneth cell numbers were quantified. While there was a ~2.5-fold increase in 
intraluminal lysozyme staining, there was a slight reduction in the relative number Paneth 
cells positioned in the ileal organoid epithelial monolayer (Figure 4C,D). Together these 
data suggest that IL22 does not cause appreciable differentiation defects of ISCs, but 
promotes the production and secretion of lysozyme from existing Paneth cells.   
 
IL22 causes a decrease in ISC biomarkers and pathways that maintain ISC self-
renewal 
 We next questioned whether IL22 increased the proliferation and self-renewal 
properties of ISCs since ileal organoids demonstrated significantly increased size when 
treated with elevated IL22. Ileal organoids treated with 500 pM of IL22 demonstrated a 
significantly higher number of KI67+ cells in the epithelial monolayer (Figure 5A). We 
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evaluated the mRNA levels for ISC biomarkers Lgr5 and Olfm4, and contrary to 
predictions, found these ISC biomarkers to be significantly down-regulated suggesting 
there was a decrease in ISC numbers (Figure 5B). Expression of key Wnt- and Notch-
pathway genes, which support ISC survival, proliferation and self-renewal135-137, were 
significantly downregulated in response to IL22 (Figure 5C-D). While Wnt3 and b-catenin 
(Ctnnb1), which tightly control ISC function and proliferative capacity, were not 
significantly changed in response to IL22, the Wnt responsive target Axin2 was 
downregulated 2-fold in response to IL22 suggesting a reduction of ISC self-renewal 
pathway inputs (Figure 5C). The Notch1 receptor ligands Dll1 and Dll4 and downstream 
target Hes1 were downregulated following exposure to IL22 (Figure 5D); however, there 
was no significant change in Atoh1 (Figure 5D), which is directly inhibited by Notch and 
required for secretory cell differentiation138. This result is consistent with no substantial 
changes in secretory lineage allocation in organoids and single ISCs exposed to IL22. 
Overall, downregulation of ISCs biomarkers and signaling pathways that regulate and 
maintain functional ISCs suggests there are lower ISC numbers or impaired ISC self-
renewal properties in ileal organoids exposed to elevated IL22. 
 
IL22 limits ISC expansion 
 Since gene expression studies suggested IL22 caused a reduction in ISCs, we 
sought to test ISC functional properties when ISCs were exposed to elevated levels of 
IL22. Serial passaging is used extensively in the hematopoietic stem cell field to assay 
stem cell function139, and here we used this strategy to assay ISC function in the presence 
of elevated IL22. In vivo studies strongly suggest that ISCs primarily divide symmetrically 
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to generate two ISCs, and thus are able to expand their numbers to maintain the proper 
balance of ISCs in the crypt base3. With this mechanism in mind, every passage of 
organoids to single cells should produce a clonal organoid derived from the number of 
ISCs found in the original organoid. During organoid ontogeny from a single ISC, ISCs 
undergo symmetric expansion to produce more ISCs/organoid; and conceptually, upon 
each passage the extent of the symmetric ISC expansion is measured by the increase in 
organoid numbers. Ileal organoids were allowed to establish in culture for 1 day, then 
were exposed to IL22 for 6 days followed by dissociation to single cells and re-plating 
(defined as passaging). Organoids were passaged 4 times over ~4 weeks. In untreated 
controls, organoid numbers increased with each passage, indicating symmetric division 
and expansion of ISCs (Figure 5E). By contrast, treatment with IL22 suppressed the 
ability for organoid numbers to increase with passage (Figure 5E). Although IL22 limited 
ISC expansion, it did not completely ablate ISCs, as a similar number of organoids were 
observed throughout all 4 passages in response to IL22. These data suggest that IL22 is 
not explicitly toxic to ISCs, but rather is limiting expansion by regulating symmetric 
division.  
 
Elevated IL22 in vivo causes an increase in proliferative cells in the TA progenitor 
zone 
While there is a significant increase in proliferating cells in ileal organoids treated 
with elevated levels of IL22, there was no increase in functional ISCs based on organoid 
passaging experiments. Based on this, we hypothesized that the increase in proliferating 
cells observed in IL22-treated organoids was due to an increase in TA progenitors, not 
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ISCs. We identified an IL22 transgenic mouse model (IL-22TG) that was used to study 
the role of IL22 in liver disease140. These mice express high levels of IL22 from an 
albumin-promoter, and IL22 serum levels reach ~4-7 ng/ml, which is in the range of ~8 
ng/ml IL22 used in our ileal organoid studies140. Intestines from these mice were obtained 
and the number of proliferating cells, their location in the crypt, and the number of ISCs 
was quantified (Figure 6). 
 In the IL-22TG mice, the number of cells per crypt and crypt height increased 
(Figure 6A,B). The TA progenitor cell zone increased 2-fold (Figure 6C), and the number 
of KI67+ proliferating cells increased 1.4-fold (Figure 6D,E). To determine if this increase 
in proliferating cells was due to an increase in ISC numbers, intestinal sections were 
stained with the ISC marker OLFM4. No difference was observed in the number of 
OLFM4+ cells per crypt between control and IL-22TG mice (Figure 6F,G), suggesting that 
IL22 does not expand ISC numbers, but rather acts to expand the progenitor cell 
population.  
 
Discussion 
Defining how inflammation of the GI tract impairs ISC driven epithelial renewal 
could have profound impacts on understanding the mechanisms regulating initiation, 
progression, and resolution of IBD. Since inflammation-induced cytokines that mediate 
the immune response are found in close proximity to the ISC niche, we used an ileal 
organoid model to screen a subset of IBD-related interleukins for their impact on ISCs. 
The screen revealed that IL22 in particular decreased OFE, however, the organoids that 
survived were substantially larger and had more proliferating cells compared to controls. 
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These observations served as a foundation to test the hypothesis that IL22 was regulating 
ISC survival and proliferation.  
The IL22-dependent increase in growth was observed at levels ~14 times those 
found in the serum of patients with IBD, but interestingly the reduced OFE was only 
observed at levels ~340 times those measured in serum125. While the serum levels of 
cytokines are commonly used as a guide for ‘physiologic levels’, we questioned this 
assumption and reasoned that IL22 levels might be substantially higher in the ISC 
microenvironment. Supporting this concept, Crohn’s disease patients have an influx of 
IL22-secreting ILC3 lymphocytes in inflamed lesions134 and in colitis ILC3s increase IL22 
production in response to inflammatory stimuli141. These studies suggest there could be 
much higher IL22 concentrations in the ISC niche compared to serum IL22 levels, which 
would likely be effectively reduced due to systemic dilution and first-pass liver effects. 
Direct measurement of IL22 in the ISC microenvironment is currently not technically 
possible; however, computational modeling of IL22 concentrations in the ISC niche 
indicated that IL22 could achieve the highest levels used in this study within seconds to 
minutes after an inflammatory stimulus. Together these findings indicated that 
pathophysiologic IL22 concentrations could be much higher at the site of secretion 
compared to those measured in the peripheral circulation. These results challenge 
conventional assumptions regarding the definition of ‘physiologically relevant’ levels 
based on serum cytokine concentrations and provide a method to predict 
microenvironment concentrations, which can guide experimental design for testing IL 
doses in organoid culture systems.  
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A recently study concluded that lower levels of IL22 promoted ISC mediated 
epithelial regeneration in a mouse model of graft-versus-host disease120. Our study 
demonstrated that IL22 concentrations ~1.7 times higher inhibited ISC expansion in ileal 
organoids. Down-regulation of ISC-associated biomarkers and a decrease in ISC self-
renewal pathway gene expression also supported the interpretation of an IL22-dependent 
loss of ISC expansion, which was functionally confirmed in organoid passaging 
experiments. Yet, surviving ileal organoids exhibited a seemingly contradictory, but clear, 
increase in organoid size and number of proliferating cells. In an attempt to reconcile the 
results, we explored whether high IL22 levels had a similar effect in vivo. Consistent with 
interpretations from ileal organoid passaging experiments, high levels of IL22 in an IL-
22TG mouse showed no ISC expansion based on OLFM4 ISC biomarker expression. 
However, the mice demonstrated a substantial and significant increase in proliferating 
cells in the TA progenitor zone. Together our results suggest that high IL22 levels might 
selectively increase expansion of proliferative TA progenitor cells at the expense of ISCs 
expansion. 
Serial organoid passaging assays, in which new organoids are clonally derived 
after passaging organoids to single cells, indicated there was no ISC expansion in the 
presence of high IL22 levels. These assays also demonstrated that the number of 
organoids remained constant over time and multiple passages, suggesting that ISC 
numbers were not reduced but remained constant. In vivo studies indicate that ISCs 
expand primarily by symmetric self-renewal3. In this case ISC commitment is driven not 
by asymmetric division dynamics, but rather by migration of ISCs out of a self-renewal 
niche supporting high Wnt- and Notch-signaling7. A potential explanation for an IL22-
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dependent increase in proliferating cells with no increase in ISCs is that IL22 shifts the 
balance of symmetric self-renewal to asymmetric division where ISC division produces 
one ISC and one TA progenitor. In this case, a cellular mechanism would produce 
equivalent numbers of ISCs and TA progenitor cells after division. Our in vitro and in vivo 
results indicate that elevated IL22 levels primarily expand TA progenitor cells, which is a 
reasonable conclusion considering that the highest Il22ra1 expression was found in TA 
progenitor cell population. Increasing the pool of cells that will soon become differentiated 
epithelium may be an IL22-dependent cellular mechanism for producing the epithelial 
tissue bulk necessary to maintain barrier function in the face of chronic inflammation. 
Interestingly, inactivation of STAT3 in cochlear hair cell differentiation results in a 
shift from asymmetric to symmetric divisions of immature cells that give rise to hair cells, 
thus, activation of STAT3 signaling preserves the asymmetric division mode in this 
particular context142. In the intestinal epithelium, IL22 signals through its cognate receptor, 
IL22ra1, and activates STAT3 signaling128. It is possible that in the context of ISCs, IL22 
signals through STAT3 to promote asymmetric division of ISCs resulting in the loss of 
ISC expansion properties. We show that IL22ra1 is expressed in the majority of ISCs, 
however, there is a small subset of IL22RA1-negative ISCs (23%). This could produce a 
scenario where IL22ra1-negative ISCs regenerate the epithelium through symmetric self-
renewal, while the IL22 receptor-positive ISCs would be influenced to undergo 
asymmetric division to increase the TA progenitor pool, and ultimately the number of 
differentiated epithelial cells. This mechanism is consistent with altered stem cell division 
observed in psoriasis, where IL22 levels are elevated143, the percentage of stem cells 
decreases, and the TA progenitor cell compartment becomes enlarged144. This would 
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also explain the increased TA progenitor cell zone in IL-22TG mice and mice injected with 
IL22 to enhance epithelial repair during graft-versus-host disease120.  
While IL22-induced epithelial repair was enhanced in mouse model of graft-versus-
host disease120, studies demonstrate that elevated levels of IL22 mRNA in inflamed 
lesions of patients with Crohn’s disease correlate with impaired regeneration145,146. These 
reports indicate that IL22 alone is insufficient to resolve impaired epithelial renewal in 
chronic inflammatory conditions and may point to a more complex and deleterious role 
for high IL22 levels in IBD. High IL22 failed to support organoid development in ~43% of 
ileal crypts put into culture, possibly indicating that IL22-responsive ISCs in the crypt base 
become incompetent to drive ISC self-renewal, and thus organoid development. We 
attempted to test this hypothesis by FACS-isolation of IL22ra1-positive ISCs and single 
cell organoid assays, however, there are no commercially available antibodies that 
facilitate FACS-isolation of IL22RA1-expressing cells. Since elevated IL22 impairs ISC 
expansion in ileal organoids, chronically elevated IL22 may actually inhibit ISC-driven 
epithelial repair because of reduced expansion capabilities of ISCs in a high IL22 
environment. This potential mechanism has important implications for establishing a role 
of IL22 in acute versus chronic inflammation, where IL22 in acute inflammation enhances 
epithelial repair and rapidly replaces lost tissue through expansion and differentiation of 
the TA progenitors, while in chronic inflammation epithelial repair is inhibited by the loss 
of ISC expansion and perhaps even loss of crypts due to IL22-induced commitment to TA 
progenitors over time. Since IL22 therapies have been proposed as a therapy to enhance 
epithelial repair of the intestinal epithelium147, is important to take the potentially negative 
IL22-dependent effects on ISC expansion under consideration.  
 41 
Methods 
Mice 
All organoid experiments were conducted on C57Bl6 mice obtained from Jackson 
Laboratory (stock number: 000664). Sox9-EGFP mice, which were originally generated 
by the GENSAT Brain Atlas Project148 and have been previously characterized41,149, were 
maintained on an outbred C57Bl/6 background. All mice used in these studies were 8-12 
weeks old. All animal use was reviewed and approved by the Institutional Animal Care 
and Use Committee (IACUC) of the University of North Carolina at Chapel Hill. 
 
Crypt isolation, organoid culture and quantification 
The distal 8cm of mouse small intestine (ileum) was isolated, fileted open and 
rinsed in ice cold DPBS. The intestine was placed in 3 mM EDTA in DPBS for 15 minutes 
at 4°C with gentle agitation, then villi were gently scraped off using a pipette tip. The 
intestine was cut into 2-3 cm pieces and placed into fresh 3 mM EDTA in DPBS with 10 
mM Y27632 (Selleck Chemicals, Cat#S1049) for 30 minutes at 4°C with gentle agitation. 
Intestinal pieces were transferred to fresh DPBS with 10 µM Y27632 and shaken by hand 
for 3 minutes at 2 shakes/second to release crypts. Isolated crypts were filtered through 
100 and 70 µm filters to remove villus fragments and rinsed once with DPBS. 
Approximately 100-200 crypts were plated per 10 uL of Growth Factor Reduced Corning 
Matrigel Matrix (Corning, Cat#354230), which was polymerized for 30 minutes at 37°C in 
a tissue culture incubator before addition of overlay media. Overlay media consisted of: 
Advanced DMEM (Gibco, Cat# 12634-028), 1X N2 (Gibco, Cat#17502-048), 1X B27 
without Vitamin A (Gibco, Cat#16704-044), 1 mM HEPES (Gibco, Cat#15630-056), 1X 
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Glutamax (Gibco, Cat# 35050-079), 100 U/mL Penicillin/Streptomycin (Gibco, 
Cat#15140-122), 500 mM N-acetyl-cysteine (Sigma, Cat#A9165), 50 ng/mL recombinant 
murine EGF (Invitrogen, PMGG8043), 100 ng/mL recombinant murine Noggin 
(Peprotech, Cat#250-38), 250 µg/mL recombinant mouse R-spondin1 (R&D Systems, 
Cat#4645RS025/CF), and 10 µM Y-27632. Y-27632 was only present in the first 24-48 
hours of cell culture and was not added to subsequent media changes. Organoids were 
allowed to establish in culture for 1 day before addition of IL6, IL17, IL21 or IL22 (R&D, 
Cat#’s 406-ML, 421-ML, 594-ML, 582-ML) to cultures. Media was then changed every 2 
days after plating and cytokines were added to overlay media after each media change 
(Figure 1A). To determine organoid efficiency, the number of living organoids were 
manually counted on days 0 (before cytokine addition), 6, 9, 12 and 14 post-plating. To 
determine organoid area, 10+ organoids were chosen and imaged before cytokine 
addition on day 1 and stage positions were saved to image the same organoid on day 6. 
Organoids were randomly chosen throughout the culture simply based on organoid 
morphology (spherical shape with clearly defined borders) to determine that the organoid 
was alive and its proximity to other organoids as to be able to determine Day 6 individual 
organoid size. Organoid area was measured from images using Image J Software150 and 
day 6 measurements were compared to day 0 to determine percent area increase. 
 For serial passaging, organoids were allowed to establish in culture for 1 day 
before addition of 60 or 500 pM IL22. Media was then changed every 2 days after plating 
and cytokines were added to overlay media after each media change. The number of 
living organoids was recorded before passage and each well of organoids was passaged 
every 6 days for 4 passages. To passage, organoids and Matrigel were scraped up in 
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250 µL TrypLE Express (Gibco, Cat#12605-036) with 10 µM Y-27632 and triturated with 
a p1000 pipette tip 75 times to dissociate Matrigel and organoids. Organoids were then 
transferred to a 1.7mL microcentrifuge tube containing 250uL TrypLE Express with 10 
µM Y-27632 and incubated at 37°C for 2.5 minutes. Cells were then triturated using a 
p1000 20 times to further dissociate Matrigel and organoids, then incubated at 37°C for 
another 2.5 minutes. Cells were then pelleted, re-suspended in appropriate amount of 
Matrigel for calculated passage ratio, and plated. Cells were re-plated at a similar density 
to previous passage. Matrigel was allowed to polymerize for 30 minutes at 37°C in a 
tissue culture incubator before overlay media and IL22 was added. 
 
Western Blot 
Organoids were rinsed three times with sterile DPBS. Cell Recovery Solution 
(Corning, Cat#354253) supplemented with 10 µM Y-27632 was then added to each well 
and organoids and Matrigel were gently scraped from bottom of tissue culture plate. 
Organoids were incubated with end-over-end rotation for 45 minutes at 4°C, then pelleted 
and re-suspended in 2X RIPA buffer with 1% protease inhibitor cocktail (Sigma, 
Cat#P8340), 1% phosphatase inhibitor cocktail (Sigma, Cat#P2850), and 1 μM 
phenylmethylsulfonyl floride (PMSF; Sigma, P7626). Samples were homogenized by 
passing through a 21-gauge needle 10 times. Protein concentration was determined 
using Bradford Protein Assay Kit (BioBasic, Cat# SK3031). Proteins were separated 
using electrophoresis in a 10% acrylamide gel and transferred to GE Healthcare 
Amersham Hybond P 0.45 μm PVDF membrane (Fisher, Cat#45-004-110). Membrane 
was blocked with 5% BSA in 1XTBS with 0.1% Tween-20 for 1 hour at room temperature, 
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then incubated overnight with rotation at 4°C with pSTAT3 primary antibody (1:500, Cell 
Signaling Technology, Cat#9145) in 5% BSA in 1X TBS with 0.1% Tween-20. The 
membrane was rinsed with 1X TBS with 0.1% Tween-20, then incubated with the 
secondary antibody anti-rabbit HRP (1:1000, Jackson ImmunoResearch, Cat#111-035-
003) for 2 hours at room temperature. Clarity Western ECL Substrate (BioRad) was used 
to visualize protein bands. Western blots were imaged using FluorChem E system 
(Protein Simple). After pSTAT3 bands were imaged, membrane was re-blotted with b-
actin primary antibody (1:1,000, Abcam, Cat# ab8225) and anti-rabbit HRP secondary 
antibody. Western blot images were quantified using Image J Software150. 
 
Computational Modeling 
IL22 cytokine diffuses from ILC3 cells to influence the intestinal crypt. Estimated 
IL22 concentration used in this model was derived from literature values describing IL22 
secretion from human ILC cells129. Briefly, ELISA was used to measure secreted IL22 in 
supernatant derived from co-cultures of LPS-stimulated macrophages and a population 
of ILCs composed of 22-35% ILC3 cells, as determined by positive staining for IL22. From 
ELISA measurements obtained with a detection limit of 15.6 pg/mL, a single ILC3 cell 
determined to secrete IL22 at an average rate of 4 fg/hr. Using Fick’s first law at steady-
state, diffusion flux from a single ILC3 was modeled. Flux was calculated using the 
surface area occupied by a single ILC3 cell (19.635 μm2), the diffusion of a single 
molecule of IL22 (1 x 10-11 m2/s), and the average secretion rate of IL22 (6.94 x 10-17 
g/hr), assuming uniform secretion across the entire surface area and constant secretion 
over time. The flux of IL22 produced by a single ILC3 cell represented in the first model 
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as a circle with a radius of 2.5μm was calculated as 5.78 x 10-14 mol/m2/s. The flux of IL22 
produced by 67 cells in a lymphoid follicle represented in the second model as a circle 
with radius of 20 µm was calculated as 3.87 x 10-12 mol/m2/s. 
Finite-element analysis software COMSOL MultiphysicsÒ (Burlington, MA) was 
used to simulate the secretion rate and concentration of IL22 generated from a single 
ILC3 cell near the intestinal crypt and a lymphoid follicle containing 67 ILC3 cells. With 
previously reported values of human IL22 levels generated from patient-derived ILC3 
cells129, the Transport of Dilute Species Interface was used to generate a model of IL22 
diffusion. The model includes two simulations: 1. a single ILC3 cell with a radius of 2.5 
μm secreting IL22, and 2. a circular lymphoid follicle with a radius of 20 μm containing 67 
tightly packed ILC3 cells secreting IL22 from each cell. Both simulations model cell 
secretion as isotropic diffusion without convective mixing. The diffusion coefficient of IL22 
(1 x 10-11 m2/s) in liquid solution was conservatively estimated based upon its molecular 
weight (17 kDa) from a range of diffusion rates (from 1 x 10-10 m2/s to 1 x 10-11 m2/s) of 
signaling molecules in the 10 to 100 kDa range. IL22 has a small M. W. of 17 kDa in this 
range, and, therefore, its diffusion coefficient is expected to be toward the lower end of 
the numerical range reported131,132. 
In a previous computational model used to predict the spatial distribution of IL-4, 
the authors of this study found that IL-4 secreting cells communicate with possible target 
cells within a range of approximately 100μm151. The authors included local molecular 
processes of diffusion, degradation, internalization, and dissociation to determine that 
communication distance from a cytokine-producing cell to a target cell depends on 
several parameters but only a few variables. Parameters of low ligand diffusion, long half-
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life of the ligand, and high affinity of the target cell’s receptors can contribute to an 
increased effective communication distance, but these are biophysical properties that the 
target cell cannot regulate. Variables of the source cell, such as rate of internalization and 
dissociation, have little effect on the local cytokine distribution even when set to extremely 
fast levels. The major variable responsible for effective communication distance is the 
rate of secretion. These previous findings support the model presented here to simulate 
diffusion-dominant secretion of IL22 with parameter exclusions. The model presented 
does have its limitations, including a simplification of a closed system, despite a lymphoid 
follicle existing in an open system with continual inflow and outflow of cells. The flow of 
liquid through the modeling space was not considered, but, as liquid flow would likely 
reduce the effective concentration of the cytokine, we present a conservative model of 
IL22 diffusion and concentration dynamics.  
 
Immunohistochemistry 
Organoids in Matrigel were rinsed once with DPBS and fixed with room 
temperature 4% paraformaldehyde (PFA) for 20 minutes at room temperature. Organoids 
were then rinsed three times with 30% sucrose and incubated overnight at 4°C in 30% 
sucrose. Organoids were embedded into cryomolds with O.C.T. Compound (Tissue-Tek, 
Cat#4583), 8μm sections were cut using an OTF5000 Cryostat Microtome (Bright 
Instruments) and placed onto positively charged microscope slides and stored at -80°C. 
For immunostaining, slides were rinsed with PBS to remove O.C.T. Antigen retrieval, 
incubation in pressure cooker for 30 seconds at 120°C and 10 seconds at 95°C, was 
performed only on slides being stained for KI67 and IL22RA1. Slides were blocked with 
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protein block (DAKO, Cat#X090930-2, or Cell Signaling Technologies, Cat#15019S) for 
1 hour at room temperature. Primary antibodies were diluted in antibody diluent (DAKO, 
Cat#S080981-2 or Cell Signaling Technologies, Cat#15019S) and incubated overnight at 
4°C. Primary antibodies and dilutions used were: KI67 (rabbit, 1:100, Dako, Cat#M7249), 
LYZ (goat, 1:500, Santa Cruz, Cat#sc-12091), CD326 (rat, 1:500, Biolegend, Cat#H8201, 
Clone#G8.8), IL22RA1 (rat, 1:50, R&D, Cat#FAB42941P), OLFM4 (rabbit, 1:250, Cell 
Signaling, Cat#39141). Secondary antibodies were diluted in antibody diluent and 
incubated on slides for 2 hours at room temperature. Secondary antibodies and dilutions 
used were: anti-rabbit Cy3 (sheep, 1:1,000, Sigma, Cat#C2306), anti-goat Cy3 (donkey, 
1:1,000, Jackson ImmunoResearch, Cat#705-165-003), anti-rat Alexa Flour 488 
(Donkey, 1:1,000, Jackson ImmunoResearch, Cat#712-546-153), anti-rat Cy3 (Goat, 
1:1,000, Jackson ImmunoResearch, Cat#112-165-003). Nuclei were stained with bis-
benzamide (1:1,000) diluted in PBS. Slides were mounted using Hydromount (National 
Diagnostics, Cat#HS-106). Images were collected using Olympus IX81 or Zeiss LSM 700 
confocal microscope. Images were analyzed in Metamorph Basic (Molecular Devices) 
and Image J150.  
Intraluminal lysozyme content was quantified using the open-source image 
analysis platform CellProfiler152. Images of sectioned organoids were taken marking the 
epithelial monolayer (CD326), the epithelial nuclei (DAPI), and Lysozyme protein after 
immunohistochemical staining as previously described. Images of each organoid were 
loaded into CellProfiler in sequence and pixel intensity of each image was rescaled. 
Binary images of each marker were formed by applying an intensity threshold using a 
three class Otsu’s method with the mid-level class considered background153. 
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Thresholded DAPI and CD326 images were combined to create binary images with the 
foreground depicting the entire epithelial signal. Gaps in the foreground of the combined 
images were closed using a 10 pixel top-hat transformation resulting in a binary image 
with the epithelial element represented as a smoothed foreground154. The lysozyme 
binary image was masked by the epithelial element to remove intracellular lysozyme 
signal. The foreground area of the masked image was quantified and categorized by 
organoid treatment. 
 
Gene Expression  
Wells with organoids were rinsed once with DPBS and 200 μL RNA Lysis buffer 
(from RNAqueous-Micro Total RNA Isolation Kit, ThermoFisher, Cat#AM1931) was 
added to each well containing 50-200 organoid or 10,000 single ISCs. RNA was extracted 
from samples using RNAqueous-Micro Total RNA Isolation Kit (ThermoFisher, 
Cat#AM1931) according to manufacturer’s protocols and stored at -80°C. cDNA was 
created using iScript Reverse Transcription Supermix for RT-qPCR (BioRad, Cat#170-
8891) according to manufacturer’s protocols. cDNA was diluted 1:20 and 1 μL of diluted 
cDNA was used for Real-Time PCR using Taqman probes (see Table 1) and 
SsoAdvanced Universal Probes Supermix (BioRad, Cat#1725281) according to 
manufacturer’s protocols.  
 
Single Cell Isolation and FACS 
For Sox9-EGFP cell isolation, crypts were isolated from whole small intestine from 
Sox9-EGFP+/- mice and single cells were isolated by FACS by established 
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methods41,48,155. For wildtype cell isolation for IL22RA1 expression, crypts were isolated 
from distal half of small intestine from C57Bl6 mice. After crypt isolation, crypts were 
pelleted and re-suspended in 9 mL calcium and magnesium-free HBSS with 0.6 U/mL 
Dispase (Corning, Cat#354235), 120 U/mL DNAse (Sigma, Cat#DN25), and 10 µM Y-
27632. Cells were then vigorously shaken for 30 seconds every 2 minutes for 10-15 
minutes until a majority of the cells were single, filtered through a 40 µm filter into ice cold 
DPBS, and washed twice with DPBS. Cells were re-suspended in ISC Basal Media 
(Advanced DMEM/F12, 1X N2, 1X B27 without Vitamin A, 1mM HEPES, 1X Glutamax, 
100 U/mL Penicillin/Streptomycin) and stained with FACS antibodies on ice for 1 hour 
protected from light.  
For intracellular staining, cells were re-suspended in room temperature 4% 
paraformaldehyde, mixed thoroughly, and incubated for 15 minutes at room temperature. 
Cells were washed with 1% BSA in 1XPBS and intracellular antibodies were added to 
cells in 1X saponin permeabilization buffer in 1% BSA in 1XPBS, mixed and incubated 
for 30 minutes at room temperature protected from light. Cells were then rinsed with 
permeabilization buffer and re-suspended in 1% BSA in 1XPBS for FACS analysis. 
Extracellular antibodiy staining was done for APC-conjugated anti-CD326 (1:250, 
Biolegend, Cat#118218, Clone#G8.8). Intracellular antibody staining was done for PE-
conjugated anti-IL22RA1 (1:100, R&D, Cat#FAB4291P). Immediately before FACS 
analysis of live cells, AnnexinV Pac-Blue (1:100, Biolegend, Cat#640918) was used for 
live/dead discrimination. All FACS and flow cytometry experiments were peformed using 
a SH800Z Cell Sorter (Sony Biotechnology). For RNA isolation, 50,000 cells were sorted 
directly into 250 μL RNA Lysis buffer (from RNAqueous-Micro Total RNA Isolation Kit).  
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Statistical Analysis 
All data are mean and standard error of the mean for the various groups. Statistics 
are based on ‘n=3’ biological replicates. For comparison of one group to a reference value 
(Western blot) a one-sample t-test was performed. For the comparison of two groups, an 
unpaired t-test with Bonferroni correction was performed. For the comparison of multiple 
groups, a one-way ANOVA followed by Tukey’s multiple comparisons test or a Bonferroni 
correction was performed. All analyses of statistical significance were calculated and 
displayed in reference with the control group unless otherwise stated. All graphs were 
made and statistics were performed using Graphpad Prism version 7.0b for Mac, 
(GraphPad Software).  
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Figure 2.1. A focused screen of IBD-related cytokines reveals that IL22 causes a 
dose-dependent decrease in organoid survival and increase in organoid size. (A-
D) Ileal organoid screen for cytokine effects on intestinal epithelium. (A) Schematic of 
experimental design where ileal organoids were treated for 6 days with 100 pM IL6, IL17, 
IL21 or IL22. (B) Representative images of treated organoids after 6 days. Scale bar=100 
μM. (C) Percent change in area of organoids comparing day 0 to day 6. Technical n=10+ 
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organoids; biological n=3; significance is relative to untreated control. (D) Organoid 
efficiency relative to control organoids. Technical n=3 wells; biological n=3 mice; 
significance is relative to untreated control. (E) Organoid response to a range of 
concentrations of IL22 (0, 0.8, 4, 20, 100, and 500 pM), measured by change in organoid 
area (left Y axis, black lines, technical n=10+ organoids) and organoid survival (right Y 
axis, red lines, technical n=3+ wells) after 6 days. Biological n=3 mice/treatment; 
significance is in relation to 0pM IL22. (F) Organoid survival with 0, 60, or 500 pM IL22 
treatment. Technical n=3 wells; biological n=3; asterisks denote significance between 
treatment group and control at the designated time point. (G-H) Organoids were treated 
with 500 pM IL22 in the presence of 206 ng/mL IL22 neutralizing antibody or 206 ng/mL 
IgG of the same species. (G) Top. Representative images of treated organoids. Bottom. 
Quantification of organoid area. Technical n=10+ organoids; biological n=3; significance 
is relative to IgG-only control. Scale bar=100 μm. (H) Top. Representative Western blot 
images for pSTAT3 and b-actin. Bottom. Quantification of intensity of Western blot bands 
normalized within each blot to the band with the highest intensity. Technical n=3 blots, 
biological n=3 mice. Significance was calculated by one-way ANOVA with a Bonferroni 
correction for multiple comparisons. ns=not significant; *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001.   
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Figure 2.2. IL22ra1 is heterogeneously expressed throughout the crypt(A) Il22ra1 
gene expression profile characterized in FACS-isolated Total epithelium (CD326+), 
Absorptive/Goblet differentiated cells (Sox9-EGFPneg), TA progenitor cells (Sox9-
EGFPsublow), ISCs (Sox9-EGFPlow), Enteroendocrine/Tuft cells (Sox9-EGFPhigh), and 
Paneth cells (Sox9-EGFPhigh, CD24high). n=3; biological n=3, Significance calculated by 
one-way ANOVA with Tukey’s multiple comparisons; bars not connected by the same 
letter are statistically significant (p<0.05). (B) Left. t-SNE analysis of single cell RNAseq 
analysis of mouse small intestinal epithelium. Each color represents a different population 
defined in the original analysis based on lineage-specific transcriptomic signatures. Right. 
Table depicts the number of cells in each lineage category expressing IL22ra1. (C) Cells 
from the t-SNE profiles in graph ‘B’ highlighted specifically for expression of IL22ra1 levels 
in all epithelial cells. Darker shades of grey represent higher expression levels. Pink 
circles represent no expression. (D) The same analysis in ‘C’ except only ISCs are 
depicted. (E) The same analysis in ‘C’ except only TA progenitors are depicted. (F) 
Representative immunohistochemistry of Interleukin 22 Receptor A1 (IL22RA1) (red) and 
cell nuclei (blue) in a mouse ileal crypt. (G) FACS analysis of fixed cell populations 
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described in (A) stained for IL22RA1. Technical n=3; biological n=3. Bars represent parts 
of whole.  
 
 
Figure 2.3. COMSOL Multiphysics simulation of IL22 diffusion. (A) Representative in 
vivo image of mouse ILC3 follicle with RORgt+ ILC3 immune cells (pink) and cell nuclei 
(blue). Parameters in table were empirically determined, n=10+ measured values/mouse, 
n = 3 mice. Scale bar = 100 μm. (B) Left. Single ILC3 IL22 secretion model where values 
of IL22 concentration were calculated by computational model along a line segment with 
length of 9 μm surrounding one ILC3 cell. Right. Concentration of IL22 over time at 4 
points at 3 μm increments. (C) Left. Follicle model where values of IL22 concentration 
were calculated along a line segment with length of 21 μm. Right. Concentration of IL22 
from a lymphoid follicle over time at 4 points at 7 μm increments. 
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Figure 2.4. Cell lineage analysis in single ISCs and ileal organoids treated with IL22. 
(A) Gene expression analysis of single Sox9-EGFPlow single ISCs after 6 hours with or 
without 500 pM IL22 examining expression of differentiated cell genes. Technical n=3, 
biological n=3. (B) Gene expression analysis of organoids after 6 days with or without 
500 pM IL22 examining expression of differentiated cell genes including SI (enterocytes), 
Lyz2 (Paneth cells), Muc2 (goblet cells), and ChgA (enteroendocrine cells). (C-D) 
Immunohistochemistry staining and quantification of organoids treated for 6 days with 
IL22 then stained for Lysozyme (LYZ, red), EPCAM (green), and nuclei (blue). Technical 
n=10+ organoids; biological n=3;. (C) Left. Representative intraluminal LYZ staining (red). 
Right. Quantification of intraluminal stain. (D) Left. Representative organoid staining. 
Right. Quantification of total number of LYZ+ cells relative to total nuclei per organoid. 
Significance was calculated using an unpaired t-test relative to the untreated control. 
Scale bar=100 μM; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 2.5. IL22 limits ISC expansion. (A) Representative immunohistochemistry for 
the proliferation marker KI67 (red) and nuclei (blue) with quantification of the proportion 
of KI67+ nuclei. Technical n=10+ organoids; biological n=3. Scale bar=100uM. (B-D) 
Gene expression analysis of organoids after 6 days with or without 500 pM IL22 for (B) 
ISC-associated genes including Lgr5, Olfm4, Ascl2 and Sox9, (C) Wnt signaling pathway-
associated genes including Wnt3, Ctnnb1, and Axin2, and (D) Notch signaling pathway-
associated genes including Notch1, Notch2, Dll1, Dll4, Hes1 and Atoh1. Technical n=3, 
biological n=3 mice. Significance was calculated using an unpaired t-test relative to the 
untreated control. (E) Percent organoid increase in response to 0, 60, or 500 pM IL22 at 
each passage compared to number of organoids at initial plating at p0. Technical n=3; 
biological n=3 mice. Significance was calculated using one-way ANOVA with Bonferroni 
correction at each time point in comparison to control. + = p<0.05 for 500pM IL22 
compared to control at Passage 1. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 2.6. Elevated IL22 causes an increase in TA progenitors. Quantification of (A) 
total number of cells/crypt, (B) total crypt height, and (C) height of TA zone in control and 
IL-22TG mice. (D) Representative immunohistochemistry for the proliferation marker KI67 
(red) and nuclei (blue). Quantification of (E) percent positive KI67 cells/crypt and (F) total 
number of OLFM4+ cells/crypt. (G) Representative immunohistochemistry for the ISC 
marker OLFM4 (green) and nuclei (blue). All quantification: n = 10+ crypts/mouse, n = 3 
mice/treatment. Scale bar = 100 μm. Ns = not significant, **p<0.01, ***p<0.001. 
Significance was calculated using an unpaired t-test relative to the untreated control. 
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Gene 
Symbol 
Gene Name Life Technologies 
assay ID 
18S Eukaryotic 18S rRNA Hs99999901_s1 
SI sucrase isomaltase (alpha-
glucosidase) 
Mm01210305_m1 
ChgA chromogranin A Mm00514341_m1 
Muc2 mucin 2 Mm00458299_m1 
Lyz2 lysozyme 2 Mm00727183_s1 
Lgr5 leucine rich repeat containing G 
protein-coupled receptor 5 
Mm00438890_m1 
Olfm4 olfactomedin 4 Mm01320260_m1 
Ascl2 achaete-scute family bHLH 
transcription factor 2 
Mm01268891_g1 
Sox9 SRY-box 9 Mm00448840_m1 
Wnt3 Wnt family member 3 Mm00437336_m1 
Ctnnb1 catenin beta 1 Mm00483039_m1 
Axin2 axin 2 Mm00443610_m1 
Notch1 notch 1 Mm00435245_m1 
Notch2 notch 2 Mm00803077_m1 
Dll1 delta like canonical Notch ligand 1 Mm01279269_m1 
Dll4 delta like canonical Notch ligand 4 Mm00444619_m1 
Hes1 hes family bHLH transcription factor 
1 
Mm00468601_m1 
Atoh1 atonal bHLH transcription factor 1 Mm00476035_s1 
Table 2.1. List of Taqman probes for qRT-PCR 
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CHAPTER 3: DEVELOPMENT OF EXTRACELLULAR MATRIX SCAFFOLDS FROM 
PORCINE SMALL INTESTINE THAT SUPPORT THE PROLIFERATION AND 
DIFFERENTIATION OF INTESTINAL EPITHELIAL CELLS 
 
Overview 
Loss of any part of the intestine due to surgical resection or congenital abnormality 
can be devastating to a patient. Resection, leading to a severely shortened bowel, may 
end up being the only option for patients who experience trauma or ischemia to the 
intestine or who suffer from disease such as necrotizing enterocolitis or inflammatory 
bowel disease. Although intestinal transplants can be performed when parenteral nutrition 
and traditional bowel lengthening strategies fail to improve patient health, transplantation 
can be problematic due to low donor availability and complications from 
immunosuppressive therapy. An engineered intestine comprised of autologous cells 
would circumvent the complications associated with intestinal transplant, including the 
need for a donor and tissue rejection. However, the architecture of the small intestine is 
complex and difficult to synthetically recapitulate. An acellular intestinal ECM would be 
the ideal natural scaffold to create an intestine ex vivo, considering that a scaffold can 
retain all ECM proteins and associated growth factors and cytokines in the same pattern 
as found in vivo depending on the isolation technique156. Creation of decellularized 
scaffolds have been successful in other organs including the heart, liver, and lung. Here, 
I have optimized a procedure to decellularize porcine small intestine that retains integral 
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anatomical structures, preserves key extracellular matrix components including Collagen 
Type I and Elastin, and supports mouse epithelial proliferation and differentiation. 
 
Introduction 
When the intestine fails, no digestion of food or absorption of nutrients, electrolytes 
or fluids occurs, creating a life-threatening condition157,158. The major cause of intestinal 
failure is short bowel syndrome (SBS), defined as having less than 200 centimeters (or 
about 30%) of functional intestine, and can result from surgical resection due trauma or 
disease158. Intravenous parenteral nutrition (PN) is required for SBS patients159. While 
this alleviates the need for digestion and absorption in the intestine in the short-term while 
the intestine adapts, up to 25% of patients continue to permanently depend on parenteral 
nutrition leading to a 5-year survival of just 63% and a range of other negative effects, 
often including liver failure159,160. When PN is no longer effective, patients need to undergo 
surgery to increase the length of the intestine or receive an intestinal transplant158,159. 
Intestinal transplants are complex due to tissue rejection, high cost of transplantation, and 
lack of viable donors157. Even with transplant, prognosis is very poor, with up to 40% of 
patients experiencing rejection within the first year and ten-year patient survival at only 
29%161. A possible alternative treatment option for SBS patients is to lengthen the 
intestine by surgical implantation of a piece of engineered tissue created from autologous 
cells. This approach has the advantage of limiting tissue rejection and negating the need 
for a healthy intestinal donor162.  
 When growing patient cells ex vivo, an acellular scaffold or matrix is needed to 
support cell growth162. Decellularized matrices are attractive as a scaffold since they 
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preserve the native architecture and extracellular matrix (ECM) components, but lack 
immunogenic host cells163. Native ECM is a complicated, intertwining mix of collagens, 
fibronectins, laminins, proteoglycans, and glycosaminoglycans that are present 
throughout a tissue in 3-dimensional patterns and gradients75. The ECM provides 
structure and aids in attachment, migration, and proliferation of resident cells and is 
integral for the function of each tissue75,79. Currently, decellularized scaffolds are being 
created from whole organs such as skin, heart, liver, lung, kindey, and intestine as well 
as other tissues such as blood vessels, heart valves, adipose tissue, and cartilage164. 
Since the native ECM and associated proteins are preserved, many of these 
decellularized organs have been able to be recellularized with native cell types or used 
to treat human disease164. 
As surplus human intestine is not available, porcine intestine is an attractive source 
for creating decellularized scaffolds due to its accessibility as an unused by-product of 
the meat industry and its similarity in overall size and macro (small intestine and colon) 
and micro (crypt and villus) anatomy to human intestine165. Additionally, using intestinal 
tissue as a scaffold allows for all native ECM components to be present and in the proper 
orientation and concentration found in the native intestine156. Here, I have developed a 
protocol to efficiently decellularize full-thickness porcine small intestine and demonstrate 
its ability to support mouse small intestinal epithelial cells. Creation of an acellular small 
intestinal scaffold will create the basis for future tissue engineering of the small 
intestine117. 
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Results 
Decellularization of Porcine Intestine 
While the overall approach to perfusion decellularization is conceptually similar 
across tissues and species, optimization is essential for every application156,164. 
Essentially, cells are removed by exposing them to detergents and enzymes, while still 
preserving the underlying ECM scaffold166. I modified a previously established protocol 
that has been particularly successful in decellularizing rat liver167. This strategy is focused 
on collagen chemistry and allowed for the resulting liver scaffold to maintain native 
histology, patent vasculature, >95% of its collagens, and physiologic levels of ECM-bound 
growth factors and cytokines167. Successful modification of this protocol involved 
modifying all stages of the decellularization process. Integral modifications included the 
luminal perfusion of N-acetylcysteine (NAC) to remove mucus from the intestinal lumen, 
luminal perfusion of decellularization reagents to aid in the removal of cellular debris, 
increasing the salt concentration to account for collagens found in the intestine, and 
increasing all solution volumes and perfusion times to account for the increased size of 
the tissue. 
Porcine small intestine was obtained from a meat processing facility and 
transferred back to the lab where it was trimmed to a smaller 6-8-inch piece of intestine 
with attached mesentery and vasculature in order to easily process (Figure 3.1A). Since 
all cells are in close proximity to a vascular network (most within 50-100um of a capillary), 
vascular perfusion was an efficient method for reaching all cells and is used in most 
decellularization protocols168. However, I found that luminal perfusion was necessary to 
remove mucus and cellular debris that remained in the intestinal lumen during and after 
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luminal perfusion (data not shown). To enhance luminal perfusion, the lumen was first 
rinsed with 100mM NAC to remove intestinal mucus by a modified catheter placed into 
one end of the intestine lumen (Figure 3.1B,C). In order to perfuse through the vasculature 
and lumen, another catheter was placed into the mesenteric vasculature (Figure 3.1C). 
After vascular and luminal rinse of blood and luminal contents, the intestinal vasculature 
is no longer marked by dark blood, suggesting a patent vasculature system for perfusion 
(Figure 3.1C). 
A 4-step protocol was then followed to perfuse solutions through both the 
vasculature and luminal catheters. First, gentle delipidation was performed with 
phospholipase A2 (PLA2) and sodium deoxycholate (SDC). These solutions degrade the 
phosphoglyceride found on the cell and mitochondrial membranes to induce necrosis and 
cytolysis167. Importantly, soybean trypsin inhibitor was also added to these perfusion 
solutions to limit protease activity from dying cells. After perfusion, the perfused intestine 
appeared pale and begins to look translucent (Figure 3.1D). 
Next, a high salt solution was perfused to retain collagens and keep them 
insoluble. The most abundant type of collagen in the intestine is Type I169,170. Collagen 
Type IV, which is found in most basement membranes surrounding cells171, is also found 
throughout all layers of the small intestine172. To a lesser extent, Collagen Types II173, III, 
V, VI170, and VII174 are also present in the small intestine, further demonstrating the 
complex mix of collagens required for intestinal homeostasis. To keep all of these 
collagens insoluble during perfusion, a high salt concentration of 4.2M was used for 
perfusion175. After perfusion of the high salt solution, the perfused intestine appeared 
translucent/white in color (Figure 3.1E). 
 64 
To remove any residual nucleic acids in the scaffolds, nuclease treatment was 
performed by perfusion of DNase and RNase. A final perfusion with basal media removed 
any remaining prior perfusion solutions. The resulting intestinal scaffold was translucent 
and appears pink after final perfusion with basal media (Figure 3.1F).  
 
Intestinal scaffolds were successfully decellularized 
 Acellular scaffolds were sectioned and their histology analyzed. First, intestinal 
scaffolds were stained with bisBenzimide, which marks DNA and nuclei, to determine if 
any cells remained after the decellularization procedure. Compared with native porcine 
intestine, the intestinal scaffolds did not contain punctate nuclei, suggesting no intact cells 
remained in the scaffolds (Figure 3.2A). Minimal diffuse staining was observed, 
particularly at the villus tips, suggesting that further rinsing of the intestinal scaffold may 
be necessary to remove all traces of native nucleic acids. Co-staining with Collagen Type 
1 (Col1a1) outlined the protruding villi, allowing for a clearer visualization of the underlying 
mucosal architecture (Figure 3.2B). 
 
Intestinal Scaffolds maintain mucosal architecture and ECM patterning 
 To determine if the intestinal scaffolds retain micro architecture and ECM 
composition, scaffold histology was examined. Col1a1 and Elastin were detected by 
immunohistochemistry to visualize the overall scaffold microarchitecture. In vivo, the 
mucosal layer is organized into crypts, which invaginate into the lamina propria and 
contain mostly undifferentiated cells, and villi, that protrude into the intestinal lumen to 
increase surface area and contain mostly differentiated cells7. Immunostaining of native 
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porcine small intestine revealed that Col1a1 was mainly observed in the villi (Figure 
3.2B,C). After the decellularization procedure, a similar pattern of Col1a1 was observed 
in the preserved villi, suggesting preservation of both the micro-architecture and Col1a1 
composition of the villi (Figure 3.2B, right). Col1a1 was also observed in the outermost 
layer of the intestine, the serosa, in both native and scaffold sections (Figure 3.2C).  
 Elastin was found predominantly surrounding the crypts, between the Col1a1 
staining in the villi and the serosal layer (Figure 3.2C). Similar patterns of Elastin were 
observed between the native intestine and the intestinal scaffold (Figure 3.2C), 
suggesting retention of Elastin throughout the decellularization procedure. Importantly, 
preservation of spatial location of both of these ECMs was observed. The locations of 
porcine Col1a1 and Elastin were similar to those found in human small intestine (Figure 
3.2D), suggesting the translational applicability for porcine decellularized scaffolds.  
 
Intestinal Scaffolds support mouse epithelium 
 In order to determine if the scaffolds could support epithelial cells in vitro, I next 
cultured mouse small intestinal epithelium on the scaffolds and examined cell expansion, 
proliferation, and differentiation. The culture of small intestinal crypts, which contain 
intestinal epithelial stem cells, in an ECM-rich hydrogel results in a high survival of the 
epithelial cells and subsequent proliferation and differentiation of the epithelium32. To 
provide sterile culture conditions for the epithelial cells to interact with the scaffold, 60μm 
sections of the decellularized intestinal scaffold were placed on the bottom of a tissue 
culture plate. Mouse small intestinal crypts were isolated from Ubq-GFP mice, which 
ubiquitously express green florescent protein (GFP) in all cells, allowing the visualization 
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of live epithelium over time. Crypts were overlaid onto the scaffolds with supportive media 
and growth factors. Importantly, no other ECM substrate was supplemented in the culture 
wells. GFP+ epithelial cells were observed on the scaffolds at Day 2 and expanded in 
area through Day 10 (Figure 3.3A). No epithelial growth was observed in wells with the 
scaffold without crypts or without the scaffold with crypts (data not shown).  
 The decellularized scaffold supported epithelial growth for 21 days post-plating 
(Figure 3.3B). To confirm that the cells were epithelial, the scaffolds were fixed and 
immunostained for the epithelial cell marker CD326 (epithelial cell adhesion molecule, 
Epcam)176. Qualitatively, all nuclei on the scaffold co-localized with Epcam, suggesting 
epithelial cell expansion on the intestinal scaffolds. To determine if the cells on the 
scaffold were proliferating, cultures were pulsed with 5-ethynyl-2´-deoxyuridine (EdU), 
which incorporates into DNA during active DNA synthesis177, for 2 hours prior to fixation 
of the scaffolds. In vivo, intestinal stem cells divide approximately once every 24 hours, 
giving rise to proliferating TA progenitor cells that divide more frequently3,7. Since one 
type gives rise to the other, proliferative cells are in close proximity to each other in the 
crypt in vivo7. Clusters of proliferative Edu+ cells were observed throughout the Epcam+ 
epithelium on the scaffold (Figure 3.3C), suggesting that the intestinal scaffold is 
supportive of ISC and TA progenitor cell proliferation. 
 
Intestinal Scaffolds support differentiation of mouse small intestinal epithelial cells 
 I next wanted to determine if the epithelium was differentiating into cell types found 
in the intestinal epithelium in vivo. TA progenitor cells differentiate as the move out of the 
crypt and onto the villi, and give rise to either secretory or absorptive cell types7. The 
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more abundant secretory cell type in the villus is the mucus-secreting goblet cell, marked 
by Muc2178. Immunostaining for Muc2 showed Muc2+ cells in the epithelium on the 
scaffold (Figure 3.4A). A less abundant secretory cell type in the villus epithelium is the 
hormone-secreting enteroendocrine cell, marked by ChgA179. Immunostaining for ChgA 
showed rare ChgA+ cells in the epithelium on the scaffold (Figure 3.4B). Qualitatively, 
these differentiated cell types do not co-localize in areas of cell proliferation (Edu+ cell 
clusters), suggesting zones of proliferation and differentiation in the scaffold. Importantly, 
presence of goblet and enteroendocrine cell types suggest that the scaffold supports 
differentiation of epithelial cells found on the villus in vivo. 
 The only differentiated cell type that does not migrate out of the crypt is the Paneth 
cell, which remains at the base of the crypt to support ISCs23. Paneth cells secrete growth 
factors, create antimicrobial proteins, and are marked by Lyz25. Immunostaining for 
Lysozyme showed clusters of Lyz2+ cells in the epithelium on the scaffold (Figure 3.4C). 
Lyz2+ cells were found in close proximity and intercalated among proliferative EdU+ cells, 
similar to their pattern in vivo. Phenotypically, the Lysozyme staining of scaffold epithelial 
cells was granulated, suggesting that these Paneth cells are making Lyzosyme granules 
and functioning similarly to how they do in vivo.  
 
Discussion 
Current intestinal engineering approaches expand a small piece of patient intestine 
approximately 3-fold by mincing and reorganizing it on a scaffold180, which does not allow 
for consistently functional or therapeutic levels of tissue to be generated and relies upon 
availability of a significant amount of initial patient tissue. Alternative approaches to 
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creating autologous patient tissue lie in expanding cell types from a small patient biopsy181 
or use of induced pluripotent stem cells182 from a more abundant cell source from the 
patient. Methods have been developed to isolate and expand many of the cell types of 
the intestine in vitro; however, re-creating a patent scaffold that adequately supports all 
intestinal cell types and is large enough to substantially improve patient health is 
challenging. The use of a decellularized porcine intestine provides a scalable scaffold that 
is both similar in size to the human intestine and maintains ECM architecture and 
composition to support all intestinal cell types. 
ECM is a requirement for intestinal epithelial cell survival in vivo and in vitro32,65. 
Currently, most in vitro culture systems use Matrigel32, ECM derived from an Engelbreth-
Holm-Swarm mouse sarcoma that is not well defined and is not FDA-approved for use in 
humans. More recently, epithelial cells have also been cultured on more defined ECMs, 
including Collagen Type I66 or combinations of isolated and synthetic ECMs67 with 
success; however, these sources do not provide all the ECM found in the native small 
intestine in the proper concentration and 3-dimensional location. Our results suggest that 
an intestinal scaffold is a promising ECM source for reconstruction of the human small 
intestine ex vivo, as the architecture and organization of Col1a1 and Elastin are retained 
post-decellularization and found in similar patterns as in the human small intestine.  
A biologically relevant ECM is integral for proper cell function, as ECM has been 
shown to influence cell behavior75,183. Specifically, ECM isolated from cancerous patient 
tissue has been shown to influence niche cells differently than ECM isolated from healthy 
patient tissue184. I demonstrated that decellularized intestine can support the proliferation 
and differentiation of mouse intestinal epithelium. Although further studies need to be 
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performed characterizing the performance of the intestinal scaffold compared to other 
ECMs, our data suggest a broad use of the scaffold for the in vitro culture of epithelial 
cells in an environment that more accurately recapitulates the in vivo environment. Other 
groups have shown that acellular ECM scaffolds can be ground up and coated on 
plates167 or made into a hydrogel to suspend cells in 3-dimensional culture117,185, both of 
which may be translational to support the growth of and expand isolated human intestinal 
epithelium. Although I demonstrated the use of the procedure on a small piece of 
intestine, methods can be scaled up to decellularize more therapeutically-relevant pieces 
of intestine and associated vasculature.  
Our protocol utilizes an otherwise discarded part of the pig that is widely available 
at most meat processing plants. In 2016, 118 million pigs were slaughtered for meat186, 
highlighting the availability and ease of obtaining porcine intestines to create scaffolds for 
intestinal tissue engineering. A porcine ECM scaffold is attractive for human clinical use 
due to the minimal immunogenic response caused by scaffold placement, demonstrated 
by clinical studies using commercially available porcine SIS grafts187,188. Acellular SIS 
have been harvested by many commercial companies183 to effectively treat many health 
problems including hernias189, vaginal prolapse190, venous ulcers191, cranial and spinal 
dural defects192, and a variety of foot and ankle disorders193. The difference between 
commercially available SIS and the acellular scaffold described in this chapter is that the 
acellular scaffold maintains the ECM and architecture of all intestinal layers, which are 
integral in the recellularization process for tissue engineering applications.  
Creation of decellularized porcine small intestine opens many avenues for future 
intestinal tissue engineering. For example, ground ECM can be suspended in solution 
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and sprayed onto the luminal surface of the intestine through an endoscope or ECM 
scaffolds can be placed placed onto the intestinal surface as intestinal “band-aids”117. 
These scaffolds could even be supplemented with ISCs or antibiotics to encourage 
epithelial regeneration. The native ECM scaffold is an integral component of the ISC niche 
and therefore an invaluable component for small intestinal tissue engineering, as it would 
be void of host cells, retain its native architecture, and promote intestinal cell growth. 
Eventually, human intestinal cells could be seeded on the scaffold and grown into all 
layers of the small intestine, opening many new doors for autologous transplant and 
grafting strategies.  
 
Methods 
Pig Intestinal Tissue 
Adult, market-weight female pig intestinal tissue was obtained from City Packing 
Company (Burlington, North Carolina). Eighteen to twenty-four inch pieces of jejunum 
were dissected at the processing plant. Intestinal pieces were placed in ice cold 
DMEM/F:12 (Gibco) and transported on ice back to the lab. Before decellularization, 
intestine and attached mesentery was trimmed to approximately 6-8 inches in length and 
placed a glass tray on ice for the decellularization procedure (Figure 3.1A).  
 
Decellularization Procedure 
A 20G X 1” catheter (Exel International) was placed centrally in mesenteric 
vasculature pointing towards the intestine and secured with suture string for vascular 
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perfusion (Figure 3.2B). Vascular perfusion of DMEM/F12 (Gibco) was performed for 10 
minutes to confirm catheter placement and to remove blood from the vasculature. 
A 14G X 1¼” catheter (Exel International) was tightly fit into the smaller end of a 
1mL pipette tip, place into one end of the small intestine, and secured with suture string 
for luminal perfusion. To remove intestinal contents, the intestinal lumen was filled with 
40mL of DMEM/F:12, and the other end of the intestine was clamped with a binder clip 
(Figure 3.2B). The piece of intestine was rocked back and forth on the glass tray at 1 
cycle/second by hand for 1 minute. Luminal contents and media were discarded by 
removal of the binder clip. Luminal washing was performed again with 50mL of 100mM 
N-acetyl-L-cystine (NAC, Sigma) in DMEM/F:12. A final wash of the intestinal lumen was 
performed with 20mL DMEM/F12 to remove residual NAC and intestinal contents.  
Clear silicone tubing (L/S 13, Cole Parmer, Cat#SK-96410-13), was attached to 
each catheter with a male luer lock ring x 1/16” hose barb (Cole Parmer, Cat#SK-45505-
00). Both vascular and luminal perfusion was performed simultaneously for the remainder 
of the procedure at a rate of 5mL/minute using a Masterflex L/S pump (Cole Parmer). 
First, DMEM/F12 was perfused for 10 minutes total. Next, two rounds of 66ml of 
DMEM/F:12 and 6 units of Phospholipase A2 (PLA2) from porcine intestine (Sigma-
Aldrich) was perfused. The PLA2 solution was made twice for this step to limit the amount 
of PLA2 degradation during perfusion. Next, 25mL 1% Sodium Deoxycholate (SDC) 
(Sigma) in 1X PBS, 0.025g Ca2+Cl-, and 2 units of PLA2 was perfused ten times. This 
solution was also made fresh 10 times to limit the amount of PLA2 degradation during 
perfusion. The intestine was then perfused with DMEM/F:12 for 30 minutes. Next, 500mL 
of 4.2M NaCl in sterile water was perfused. The intestine was then perfused again with 
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DMEM/F:12 for 30 minutes. Next, 100mL DMEM/F:12, 0.001g DNase, 5mg RNase, and 
0.01g Trypsin inhibitor from Glycine max (Sigma) was perfused. A final perfusion of 
DMEM/F12 was performed for 30 minutes. 
 
Sectioning Intestinal Scaffolds 
The resulting intestinal scaffold was embedded either fixed or fresh. If fixed, the 
scaffold was placed in in ice cold 4% paraformaldehyde overnight at 4°C, rinsed with 30% 
sucrose, and stored in 30% sucrose overnight at 4°C. If fresh, intestinal scaffolds were 
placed in 30% sucrose for 2 hours at 4°C. All scaffolds were then embedded into 
cryomolds with O.C.T. Compound (Tissue-Tek, Cat#4583). For immunohistochemistry 
experiments, 8μm sections of fixed scaffolds were cut using an OTF5000 Cryostat 
Microtome (Bright Instruments), placed onto positively charged microscope slides, and 
stored at -80°C until use. For culture experiments, 60μm sections of fresh scaffolds were 
cut and placed in the bottom of wells in a 12-well tissue culture plate. Sections were dried 
in a sterile tissue culture hood for one hour at room temperature. Each scaffold was rinsed 
five times with 1X DPBS (Gibco) supplemented with 100U/mL Penicillin/Streptomycin 
(Gibco) for 5 minutes. Scaffolds were overlaid with Advanced DMEM/F:12 with 100U/mL 
Penicillin/Streptomycin until cell seeding. 
 
Human Intestinal Tissue 
Human intestine was obtained from deceased organ donor patients from Carolina 
Donor Services. Human tissue used in this study qualified as exempt after full Institutional 
Review Board review (approval #14-1750). Full-thickness jejunum was isolated from the 
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small intestine and fixed in cold 4% paraformaldehyde overnight at 4°C. Jejunum was 
rinsed with 30% sucrose and stored in 30% sucrose overnight at 4°C. Small, full-thickness 
pieces of jejunum were embedded into cryomolds with O.C.T. Compound (Tissue-Tek, 
Cat#4583). Sections (8μm) were cut using an OTF5000 Cryostat Microtome (Bright 
Instruments), placed onto positively charged microscope slides and stored at -80°C. 
 
Mice  
Mice expressed enhanced green fluorescent protein (GFP) under the direction of 
the human ubiqutin C promoter (Ubq-GFP). Mice were originally purchased from Jackson 
Labs (Strain Name: C57BL/6-Tg(UBC-GFP)30Scha/J, Stock Number: 004353) and were 
maintained as homozygotes. All mice used in these studies were 8-12 weeks old. All 
animal use was reviewed and approved by the Institutional Animal Care and Use 
Committee of the University of North Carolina at Chapel Hill.  
 
Mouse Intestinal Crypt Isolation, Plating, and Culture 
The jejunum (middle 1/3 of small intestine) of the mouse was isolated, flushed, 
fileted open and rinsed in ice cold 1XDPBS. The intestine was cut into 3-5cm pieces and 
placed in 3 mM EDTA in 1XDPBS for 45 minutes at 4°C on an orbital rocking platform. 
Intestinal pieces were then transferred to 1X DPBS with 10 μM Y-27632 (Selleck 
Chemicals) and shaken by hand for 2 minutes at 3 shakes/second to release crypts. 
Isolated crypts were filtered through 100 and 70 μm filters to remove villus fragments and 
rinsed once with DPBS. 
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One thousand isolated crypts were plated in each well of 6-well plate (with or 
without a scaffold) with 250uL Overlay media/well. Overlay media consisted of 50% 
Advanced DMEM/F12, 50% RSPO2 conditioned media (made in-house), 100ng/mL 
recombinant murine Noggin (Peprotech), 50ng/mL recombinant murine EGF (Invitrogen), 
100X Glutamax (Gibco), 100X N2 Supplement (Gibco), 50X B27 Supplement (Gibco), 
1mM Hepes (Gibco), 500mM N-acetylcystine (NAC, Sigma), 100U/mL 
Penicillin/Streptomycin (Gibco), and 50g/mL Gentamicin. Media was changed every other 
day, being careful not to disturb underlying scaffold. 
Stage positions within wells were saved on Day 2 and imaged on Days 2, 6 and 
10 post-cell plating using an Olympus IX81 microscope to serially observe the same 
scaffold section over time. Mouse epithelial cells expressed GFP and were able to be 
visualized by excitation at 488 nm. To mark proliferating cells, epithelium on scaffolds 
were pulsed with 20uM 5-ethynyl-2’-deoxyuridine (EdU) for 2 hours after 21 days in 
culture. Cells were rinsed with 1DPBS and fixed for at room temperature for 20 minutes 
with room temperature 4% paraformaldehyde. Wells were then rinsed 3 times with 3% 
BSA in 1XDPBS and stored in 3% BSA in 1XDPBS until whole mount staining.  
 
Immunohistochemistry 
For immunostaining sections, slides were rinsed with PBS to remove O.C.T. Slides 
were blocked with Protein Block (DAKO) for 1 hour at room temperature. Primary 
antibodies were diluted in Antibody Diluent (DAKO) and incubated overnight at 4°C. 
Primary antibodies and dilutions used were: CD326 (Epcam; anti-mouse, primary 
conjugated to Alexa647, 1:250, Biolegend, Cat#118211, Lot#B15046), Anti-Collagen 
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Type I (mouse, 1:300, Sigma-Aldrich, Cat#C2456), and Anti-Elastin (rabbit, 1:100, 
Abcam, Cat#21610). Secondary antibodies were diluted in antibody diluent and incubated 
on slides for 2 hours at room temperature. Secondary antibodies were all diluted 1:1,000 
in antibody diluent and were: Goat anti-mouse, Cy3, Jackson ImmunoResearch, 
Cat#115-166-003; and Goat anti-rabbit, 488 AlexaFluor, Jackson ImmunoResearch, 
Cat#111-545-144). Nuclei were stained with bisBenzamide (1:1,000) diluted in PBS for 
10 minutes at room temperature. Slides were mounted using Hydromount (National 
Diagnostics, Cat#HS-106). Images were collected using an Olympus IX81 microscope.  
 For whole mount immunohistochemistry, the Click-iT EdU Imaging kit with Alexa 
Fluor 555 (Invitrogen) was used to visualize EdU labeling. Protocol was followed per 
manufacturer’s instructions. Further antibody staining was performed after EdU detection. 
Primary antibodies were diluted in antibody diluent and incubated overnight at 4°C. 
Primary antibodies and dilutions used were: CD326 (Epcam; anti-mouse, primary 
conjugated to Alexa647, 1:250, Biolegend, Cat#118211, Lot#B15046), Lyz2 (rabbit, 
1:500, Diagnostic Biosystems, Cat# RP028), Muc2 (rabbit, 1:500, Santa Cruz, Cat# sc-
15334), and ChgA (goat, 1:100, Santa Cruz, Cat# sc-1488). Secondary antibodies were 
diluted in antibody diluent and incubated on slides for 2 hours at room temperature 
protected from light. Secondary antibodies were all diluted 1:1,000 in antibody diluent and 
were: Donkey anti-goat Alexaflour 488 (Jackson ImmunoResearch, Cat#705-475-147), 
Goat anti-rabbit Alexaflour 488 (Jackson ImmunoResearch, Cat#111-545-144), Donkey 
anti-rabbit Alexaflour 647 (Jackson ImmunoResearch, Cat# 711-605-152). Nuclei were 
stained with bisBenzamide (1:1,000) diluted in PBS for 10 minutes at room temperature. 
Scaffolds were stored in 1XDPBS at 4°C until imaging. 
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Figure 3.1. Porcine intestine throughout the decellularization process. (A) 
Vasculature (dark blue) is found in both the mesentery (yellow) and throughout the small 
intestine. (B) Luminal rinsing is achieved by placing a catheter into one end of the 
intestinal lumen and clamping off the other end with a binder clip. (C) Vascular and luminal 
perfusion is achieved by a catheter (top left) placed into the vasculature and a modified 
catheter (top right) placed the intestinal lumen. (D-F) A gross color change of the intestinal 
tissue from opaque to white/translucent throughout the decellularization procedure. 
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Figure 3.2. Intestinal scaffolds retain architecture and ECM composition. (A) Native 
porcine small intestine (left) and decellularized intestinal scaffold immunostained for 
nucleic acid (blue). (B) Mucosa of native intestine (left) and intestinal scaffold (right) 
immunostained for Col1a1 (red) and nuclei (blue), highlighting the intact villus architecture 
of the small intestine. (C) Full-thickness native intestine (left) and intestinal scaffold (right) 
immunostained for Col1a1 (red), Elastin (green) and nuclei (blue) demonstrating retention 
of ECM. (D) Human small intestine immunostained for Col1a1 (red), Elastin (green) and 
nuclei (blue) demonstrating similar ECM patterning to porcine intestine. Scale bar = 
100μM.  
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Figure 3.3. Intestinal scaffolds support intestinal epithelial cell proliferation. (A) 
Representative images of sixty micron sections of intestinal scaffold and Ubq-GFP 
intestinal epithelium (green, top) 2, 6, and 10 days post-epithelial seeding. Bright field 
images (bottom) show cell seeding on scaffolds. (B) Cells on scaffolds are marked by 
nuclei (blue) and the epithelial cell marker Epcam (red). (C) Edu+ proliferating cells 
(yellow) are marked by nuclei (blue) and Epcam (red). EdU+ cells (yellow) are found in 
small clusters, similar to spatial organization in crypts in vivo. Scale bar = 100μM 
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Figure 3.4. Intestinal scaffolds support intestinal epithelial cell differentiation. (A) 
Immunostaining for Muc2+ goblet cells (green), Edu+ proliferating cells (yellow), and 
nuclei (blue). (B) Immunostaining for ChgA+ enteroendocrine cells (green), Edu+ 
proliferating cells (yellow), and nuclei (blue). (C) Immunostaining for Lyz2+ Paneth cells 
(green), Edu+ proliferating cells (yellow), and nuclei (blue). Scale bar = 100μM 
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CHAPTER 4: SCOPE OF WORK, SIGNIFICANCE, AND IMPLICATIONS FOR 
FUTURE STUDIES 
 
IL22 levels are physiologically important 
Interaction between the local and recruited immune cells in the intestine has been 
studied in the context of interaction with the epithelium as a whole84; however, few studies 
specifically investigate the effect that immune cells have on the ISC. In Chapter 2, an in 
vitro model of ileal ISCs was utilized to determine the specific effect that recombinant IBD-
related cytokines played on ISC dynamics. This screening approach is attractive to 
identify ISCs reactions to exogenous factors and recent technological advances have 
made this type of assay even more specific and high-throughput48. The approach of the 
in vitro model system allowed for the specific interaction of IL22 and ileal ISCs, which 
interact in vivo during inflammation, to be studied in a controlled, reproducible 
environment, which is a strength of the study as a whole. Ultimately, these studies 
revealed a dose-dependent effect of IL22 on ISCs isolated from the ileum, suggesting a 
novel, dual role of IL22 in the small intestine where low levels encourage ISC regeneration 
and high levels promote TA progenitor cell proliferation and differentiation. This anti-
inflammatory role of IL22 at low levels is supported by clinical data from patients with mild 
to moderate Crohn’s disease being treated with Ustekinumab (Stelara), which blocks 
Interleukin 23, and in turn lowers IL22 levels194,195. Use of Ustekinumab in Crohn’s 
disease patients that did not respond to TNF-alpha therapy has showed great promise 
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with a majority of patients showing clinical response194, suggesting that lowering levels of 
IL22 may lead to disease remission.  
IL22 has also recently been the direct focus of therapeutics for the treatment of 
intestinal epithelial would healing, as IL22 has been suggested to directly promote ISC 
regeneration120. In mouse models of graft-versus-host disease, the use of an IL22 fusion 
protein that stabilizes IL22, increased survival and decreased disease pathology120. Since 
then, a human IL22 fusion protein, known as “IL22-Fc” or “UTTR1147A”, has been 
developed by Genentech and is currently in Phase I clinical trials for patients with 
ulcerative colitis. The implications of increasing IL22 in a human patient is more complex 
than an in vitro model system, considering the diffusion rates of IL22 throughout the body, 
supplemental IL22 degradation, and the presence of IL22BP and its ability to sequester 
IL22 before it interacts with epithelial cells. Measurement of IL22 that actually reaches the 
intestinal epithelium and interacts with the ISCs during therapy is challenging; however, 
it may be indirectly estimated by intestinal mucosal biopsy, where the regenerative 
capacity of ISCs can also be assessed in response to elevated IL22 levels. Nevertheless, 
the clinical consequence of elevated levels of IL22 should be closely monitored in light of 
the data presented in Chapter 2. The long-term use of IL22 supplementation should also 
be carefully examined as accumulation of IL22 may also lead to prolonged inflammation.  
The data presented are limited in their applicability to intestinal inflammation in the 
intestine as a whole, as they focus on one cytokine in one region of the small intestine. 
However, the intestine is dynamic and each region has a specialized epithelium and 
immune system10, so investigation into segment response is needed to fully understand 
how regional populations ISCs respond to inflammation. Previous investigation into the 
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influence of IL22 on ISCs isolated ISCs from the whole small intestine120, which limits the 
physiological relevance of the findings since IL22-secreting cells, inflammation, and 
Crohn’s disease are all less abundant in the proximal small intestine. However, the 
described in vitro assay, as well as the methods of investigation outlined in Chapter 2 can 
be easily translated to other cytokines, other regions of the gastrointestinal tract, or other 
species of ISCs. 
The work presented in Chapter 2 has been reviewed at Cellular and Molecular 
Gastroenterology and Hepatology and is currently in revision. In order to strengthen the 
revised manuscript, I plan to further characterize the organoids after IL22 exposure and 
more precisely characterize the spatial location of ILC3s within the mouse ileum. 
Reviewers were interested in the mechanism for increased Reg family gene expression, 
with the suggestion that it may be in part due to upregulation of NOD2. I will investigate 
the effect that NOD2 has on the expression of the Reg family of antimicrobials by treating 
NOD2-knockout organoids with IL22 and it is expected that IL22 will not be able to 
upregulate Reg3b and Reg3g without NOD2 present. Additionally, the concept of 
autophagy was briefly discussed in the manuscript, as autophagy in response to bacterial 
sensing has been shown to be NOD2-dependent and NOD2 was found to be upregulated 
with IL22 treatment. I will measure autophagy by Western blot analysis for Microtubule-
associated protein 1A/1B-light chain 3 (LC3), which is recruited to autophagosomal 
membranes. It is expected that IL22-treated organoids will have an increased expression 
of LC3-II, suggesting increased autophagy as well as an explanation for the decrease in 
Paneth cell numbers. Finally, we will provide a more accurate computational model of 
ILC3 secretion of IL22 by defining parameters associated with ILC3s in vivo. I will perform 
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immunohistochemistry on sections of mouse ileum for RORyt, which marks IL22-
producing ILC3s in the intestine, to determine the distance between ILC3s and ISCs, 
innate lymphoid follicle size, and the number of ILC3s per follicle. 
 
Acellular porcine intestine is an attractive scaffold for intestinal tissue 
engineering 
Underlying the epithelium and supporting all cell types in the intestine, the ECM is 
integral to ISC survival both in vivo and in vitro. The mesenchyme of each tissue is 
specifically tailored to promote the attachment, migration, and proliferation of resident 
cells75,79. Use of this naturally occurring scaffold for tissue engineering gives a distinct 
advantage over synthetic scaffolds as it retains the architecture and protein composition 
in the proper 3-dimensional gradients and patterns75. Decellularized scaffolds have also 
been shown to retain ECM-associated glycosaminoglycans as well as bound growth 
factors and cytokines, allowing for other organs to be successfully de- and re-cellularized, 
including the liver, heart, lung, and kidney196.  
 The data presented in Chapter 3 is only the start of the process of creating the 
optimal acellular intestinal scaffold. Current defined criteria for effective decellularization 
include: removal of cells and DNA content, quantification of residual detergents, 
preservation of ECM components, maintenance of 3D architecture and vascular integrity, 
and biomechanical performance196. The lack of nuclei present and retention of two major 
ECM proteins post-decellularization are promising for the future translational use of the 
described intestinal scaffolds. Most importantly, the intestinal scaffold supports the 
growth, proliferation and differentiation of mouse ISCs without the need for exogenous 
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ECM, such as the previously required Matrigel or Collagen Type I substrates. This 
suggests that the acellular scaffold has all ECM components necessary to support 
epithelial cell growth and highlights its translational potential as a scaffold to support 
human cell growth. However, extrapolation of the abilities of the scaffold are limited as 
only mouse primary epithelial cells were tested for their compatibility with the scaffold in 
a 2-dimensional assay using thin sections of the acellular scaffold. The next steps in 
intestinal scaffold development include confirming that acellular scaffolds met established 
decellularization criteria, decellularizing larger pieces of intestine, and reperfusing 
intestinal cell types through the patent vasculature.  
 Development of an acellular intestinal scaffold will be useful in many future 
applications. As previously discussed, porcine intestinal tissue is a by-product of the 
agriculture industry; therefore, the starting material for large pieces of intestine are readily 
available and decellularization techniques can be scaled up to incorporate 
physiologically-relevant sized pieces of intestine. Although the completion of a full-
thickness bioengineered intestine is still far off, the use acellular intestinal scaffolds can 
have a more immediate use. For intestinal-specific therapies, acellular intestinal ECM 
could be used as a “band aid” to patch ulcers associated with IBD by providing a substrate 
for epithelial and mesenchymal cells to interact with. Furthermore, this “band aid” could 
be enhanced with antimicrobials to help limit invasion of microbes and/or growth factors 
to help promote epithelial regeneration. More specific decellularization of ECM found 
surrounding the crypts versus villi may also differentially influence intestinal cell 
proliferation and differentiation, providing a more specific ECM substrate to promote 
epithelial regeneration. Isolated ECM from other tissue sources has been ground up into 
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a powder or made into a hydrogel, further displaying the potential therapeutic benefits of 
acellular ECM117. An intestinal ECM hydrogel could coat tissue culture plates as a more 
physiologically relevant substrate for in vitro intestinal cell culture or be sprayed on ulcers 
through a colonoscope117. 
 The research and development of this project highlights the complexity of the 
intestinal ECM and its integral influence on both intestinal homeostasis and recovery from 
damage. The requirement of a specific ECM for the proper proliferation and differentiation 
of ISCs and other cell types suggests the idea of dynamic reciprocity in the intestine. 
Dynamic reciprocity is a long-standing theory and explains the ongoing, bidirectional 
interaction between cells and ECM and has been thoroughly investigated in regenerative 
models including wound healing and tumorigenesis where resident cells and ECM are 
being remodeled197. However, little is known about the concept of dynamic reciprocity in 
the intestine between the ECM and the many cell types in is in contact with. To further 
investigate this concept, the interaction between the ECM, myofibroblasts, and ISCs was 
the focus of my Ruth L. Kirschstein Predoctoral Individual National Research Service 
Award (F31DK107137). The focus of this fellowship was to investigate the role of 
Collagen XVIII (Col18a1), which found in the basement membrane in the ISC niche and 
able to sequester Wnts. Although initially thought to be made in epithelial cells, single cell 
RNA-seq and immunohistochemistry revealed that Col18a1 was not of epithelial origin. 
Col18a1 was found to be expressed in myofibroblasts within the lamina propria 
surrounding the crypts. Interestingly, single cell RNA-seq revealed an increased number 
of colonic myofibroblasts expressed Col18a1 during colitis, suggesting a role for Col18a1 
during intestinal damage and regeneration. Although the data were not presented in this 
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dissertation, these findings have led to interesting insights into how the supportive ECM 
created by surrounding myofibroblasts is dynamic and heterogeneous, suggesting that 
the ECM in the niche is complex and may influence ISC proliferation and differentiation. 
These findings provide even more support towards using a native ECM scaffold for 
intestinal engineering, as recapitulating the complex microenvironment will be challenging 
using individual or synthetic scaffolding materials.  
 
Extrinsic niche factors influence ISC proliferation and differentiation 
 The data presented in this dissertation adds to an ever-expanding field of 
gastrointestinal research by: 1. Identifying a dose-dependent role for IL22, where elevated 
levels of IL22 limit ISC expansion, and 2. Developing a small intestinal acellular scaffold 
that supports ISC proliferation and differentiation. Together, these to findings underscore 
the importance of extrinsic niche signaling on ISC proliferation and differentiation. Niche 
factors are integral for the survival and proliferation of ISCs; therefore, understanding the 
ISC environment during homeostatic, damage, and regenerative responses is important 
for the development of therapeutics for patient health. The scope of work presented here 
is limited to the small intestine; however, it provides the basis and rationale to continue 
investigation into ISC niche interactions to further understand human health. 
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APPENDIX A: ORGANOID CULTURES FOR ASSESSING INTESTINAL EPITHELIAL 
DIFFERENTIATION AND FUNCTION IN RESPONSE TO TYPE-2 INFLAMMATION1 
 
Overview 
During helminth infection of the gastrointestinal tract, a complex Type-2 
inflammatory response involving immunological and mucosal components is mounted to 
clear the infection and re-establish a physiologically normal state. This response is 
characterized by the secretion of key interleukins, which impact epithelial lineage 
allocation and drive tuft and goblet cell hyperplasia to lead to eventual clearance of 
parasitic organisms. While there have been advances towards understanding Type-2 
inflammatory responses in the intestine, detailed cellular and molecular mechanisms of 
epithelial responses to general inflammation and specific inflammatory cytokines remain 
to be explored. Intestinal organoids represent a physiologically relevant in vitro model to 
study how Type-2 inflammation impacts stem cell maintenance and differentiation, and 
offer a new approach for investigators to test compounds that modulate mechanisms 
involved in worm clearance. The methods described in this chapter include: (1) intestinal 
crypt and single cell isolation, (2) organoid culture and cytokine treatment, as well as 
methods for downstream organoid analyses: (3) gene expression analysis by qRT-PCR, 
(4) protein analysis by western blot, immunohistochemistry, and florescent-activated cell 
sorting, and (5) organoid self-renewal by serial passaging. 
 
1This chapter will appear as a book chapter in Type 2 Immunity: Methods and Protocols 
(Methods in Molecular Biology), “Organoid cultures for assessing intestinal epithelial 
differentiation and function in response to Type-2 inflammation”, 2018, Bailey Zwarycz, 
Adam D. Gracz, Scott T. Magness. ©Springer Science+Buisness Media LLC. With 
permission of Springer Nature. 
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Introduction 
The gastrointestinal tract is a complex organ that functions as the site of nutrient 
and water absorption at the interface of the lumen and the epithelial monolayer. The 
lumen is home to a vast number of commensal microbiota that exist in a symbiotic 
relationship with the host organism, and while these microbiota play a critical role in 
health, it is essential that they are restricted to the luminal compartment by an 
uncompromised epithelial monolayer. The epithelial barrier can be compromised by 
physical injury or by pathogenic microbiota that are ingested by the host. When this occurs 
acutely on a large scale the host may succumb to sepsis, but at the chronic small scale 
the host may develop conditions associated with inflammatory bowel disease (IBD). A 
host infected with pathogenic microbes may not present with clinical symptoms because 
on an insufficient inoculum, inability of pathogenic strains to outcompete the commensal 
communities, or because of efficient physiologic clearance by the host immune system. 
Surveillance of pathogenic microorganisms by the intestinal epithelium requires complex 
coordination between the epithelial cells that serve as the primary barrier to luminal 
contents and other submucosal cell types that actuate the immune response. Epithelial 
Tuft cells have an essential role in monitoring the luminal environment for parasitic 
infection and communicating this information to the underlying immune cell compartment 
that responds to the infection198-202.  
Tuft cells are one of six primary differentiated lineages found in the intestinal 
epithelium, and until recently, their function remained unknown. Decades ago, tuft cells 
were first described as ‘Brush cells’ based on the presence of apical tufts of stiff 
microvilli202. In homeostasis, Tuft cells are considered a very rare epithelial cell (~0.4% - 
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1.0%), however, following infection of the host by helminths, a type of microscopic worm, 
the intestinal epithelium undergoes tuft cell hyperplasia (~7.2%) in an effort to clear the 
worms199. Aside from morphological identification, a number of biomarkers are now 
associated with the tuft cell lineage including: Dclk1, Cox1, Plcg2, Gfi1b, Trpm5, and high 
levels of Sox921,28,199,200. At a transcriptomic level, tuft cells demonstrate a Th2 gene 
expression signature suggesting that they have the capacity to respond to infection 
through a specific interleukin response203. Recent studies confirm this prediction by 
showing that tuft cells are involved in a positive feedback circuit initiating a Type-2 
immune response to helminth infection198-200. 
In the intestine, Type-2 immune responses are commonly associated with helminth 
parasitic infection, but also participate in IBD204. CD4+ lymphocytes are classically known 
as a mediator for Th2 immunity, but a subset of innate lymphoid cells known as ILC2 cells 
in the submucosa are now recognized as key mediators of Th2 responses in the intestine. 
ILC2 cells are characterized by expression of IL-4, IL-5, and IL-13 which in turn activate 
other immune cell types (basophils, mast cells, and eosinophils) that assist in clearing the 
infection205. Tuft cell function involves a sophisticated positive feedback loop between 
helminths, the differentiated epithelium, ILC2s, and the undifferentiated stem/progenitor 
cell compartment (Figure 5.1) 198-200. Upon parasitic infection, tuft cells detect the 
presence of helminths or protozoa through a Trmp5-dependent chemosensory 
pathway199. This causes tuft cells to secrete IL-25 that in turn acts on submucosal ILC2 
cells (Figure 5.1A), which secrete IL-13 (Figure 5.1B).  ILC2 cells are in close proximity 
to the stem/progenitor cell compartment and the IL-13 secreted by ILC2 cells promotes 
lineage bias toward tuft and goblet cells (Figure 5.1C, D). Goblet cell hyperplasia has a 
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dual function to increase mucous to protect the epithelium and aid in worm clearance, 
while tuft cell hyperplasia serves to increase sentinels to monitor and respond to the worm 
infection. Increases in tuft cell numbers continue to fuel the IL-25 positive feedback during 
infection (Figure 5.1E). Reduction in worm burned serves as a break to tuft and goblet 
cell hyperplasia and the epithelium returns to homeostasis (Figure 5.1F). While significant 
strides have been made to understand the cellular mechanisms regulated by the tuft cell-
ILC2 axis, much remains to be investigated related to the impact of other Th2 cytokines 
on ISC differentiation, the specificity of tuft cell responses to different helminth species, 
and additional roles that tuft cells may play in regulating the microbiome in heath and 
disease.  
Animal models have served a critical role in moving the Th2-field forward; however, 
there is substantial merit for using culture models to address questions that are not 
feasible in animal models, and to develop ex vivo platforms that are useful for screening 
compounds that are capable of enhancing or abrogating Th2 responses. Intestinal 
organoid technology has revolutionized in vitro study of gastrointestinal epithelial biology 
and has recently been applied to investigate Type-2 immune responses199,200. Intestinal 
organoids are stem cell driven structures derived from whole isolated crypts or single 
ISCs that can be spherical or budding in nature, depending on proliferation status48. They 
are non-transformed and are capable of growing indefinitely in a three-dimensional extra 
cellular matrix (typically Matrigel) with a defined media consisting of essential growth 
factors found in the ISC niche in vivo32,54. Nomenclature for organoids has been further 
refined as ‘enteroids’ when derived from small intestinal tissue, or ‘colonoids’ when 
derived from colonic tissue56. Organoids represent a powerful tool to study Type-2 
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immune responses due to their ability to: (1) generate all the differentiated lineages found 
in the gastrointestinal tract and (2) maintain an ISC compartment that is able to respond 
to extrinsic signals that influence ISC proliferation and differentiation. While organoids are 
comprised exclusively of epithelial cells, the cytokine environment produced by a Th2 
response can be recreated in culture media, and organoids are capable of being co-
cultured with other cell types that impact Type-2 immunity. The properties render organoid 
cultures highly adaptable and amenable to detailed mechanistic analysis. 
Organoids generated from normal mouse strains typically used in research 
settings can be readily evaluated for proliferation and differentiation by immunostaining, 
and gene expression can be interrogated by qPCR or RNA-seq analysis. While these 
standard methods are useful, a number of transgenic mouse lines that express 
fluorescent reporter gene associated with secretory lineages involved in Type-2 immunity 
enable detection and isolation of live cells for analysis. Dclk1, Gfi1b, Il25, and Trpm5 
represent biomarkers highly restricted to the tuft cell lineage21,198,199,201. A Dclk1-CreERT2 
transgenic mouse line has been developed that enables identification, isolation by 
florescent-activated cell sorting (FACS), and evaluation of tuft cells when crossed to a 
mouse line harboring conditional fluorescent reporter allele like ROSA-flox-STOP-flox-
EGFP. Additionally, Gfi1b-EGFP, IL25-RFP, and Trpm5-EGFP transgenic mouse lines 
have likewise demonstrated restricted expression to tuft cells and do not require a 
separate fluorescent reporter allele198,199,206.  
The focus of this chapter is to provide step-by-step methods for: 1) producing 
conditioned media that supplies the necessary growth factors for organoid culture, 2) 
isolation of crypts from mouse small intestine, 3) culturing crypts in ECM and conditioned 
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medial to generate organoids, 4) splitting organoids for continual maintenance in culture, 
and 5) analyzing organoids by immunostaining, qPCR, flow cytometry, and western blot 
for responses to Type-2 immune responses.     
 
Materials 
Generating Conditioned Media 
1. Cultrex R-spondin1 293T cells (Trevigen) 
2. Tissue Culture Treated Dishes 150 x 20mm (Genesee) 
3. Dulbecco’s Phosphate Buffered Saline (DPBS (1X), Gibco) 
4. Selection Media: Dulbecco’s Modified Eagle Medium (DMEM, Gibco), 10% 
Fetal Bovine Serum (Gemini), 100 U/mL Penicillin/Streptomycin (Invitrogen), 
2mM GlutaMax (Gibco), 300 µg/mL Zeocin (Thermo Fisher) 
4. Culture Media: Dulbecco’s Modified Eagle Medium (DMEM, Gibco), 10% Fetal 
Bovine Serum (FBS), 100 U/mL Penicillin/Streptomycin (Invitrogen), 2mM 
GlutaMax (Gibco) 
5. Harvest Media: Advanced Dulbecco’s Modified Eagle Medium/F12 (DMEM/F12, 
Gibco), 100 U/mL Penicillin/Streptomycin (Invitrogen) 
6. 0.22 µm bottle top filter  
7. Freezing Media: DMEM, 20% FBS, 10% Dimethyl sulfoxide (DMSO) 
 
Crypt-enriched intestinal epithelial isolation 
1. Dulbecco’s Phosphate Buffered Saline (DPBS): 1X DPBS 
2. 0.5 M EDTA, pH 8.0 
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3. 3 mM EDTA 
4. 10 cm petri dishes  
5. 70% Ethanol 
6. Dissection tools: surgical scissors, dissection forceps 
7. Glass plate 
8. 100 µm cell strainer 
9. 2X ISC Medium: Advanced DMEM/F12, 200X N2 (Invitrogen), 100X B27 without 
Vitamin A (Gibco), 2 mM HEPES (Gibco), 4mM Glutamax (Gibco), 200 U/mL 
Penicillin/Streptomycin (Gibco) (See Note 1) 
 
Organoid culture and cytokine treatment 
1. Tissue culture plate (Genessee) (See Note 2) 
1. Extracellular Matrix: Growth Factor Reduced Matrigel (Corning) or Cultrex 
(Trevigen) (See Note 3) 
2. Recombinant Interleukin 4 (IL-4)  
3. Recombinant Interleukin 13 (IL-13)  
4. 2X ISC Medium (See Note 1) 
5. ENR (EGF/Noggin/R-spondin 1) medium: 50% 2X ISC media (see above), 40% 
Advanced DMEM/F12, 10% RSPO1-conditioned media (see Section 2.1 above 
for creation of this conditioned media), 50 ng/mL recombinant murine EGF, 100 
ng/mL recombinant murine Noggin, 10 µM Y-27632 (Selleck Chemicals) (See 
Notes 4-6) 
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RNA lysis and gene expression analysis 
1. RNAqueous Micro Kit (Ambion) 
2. Dulbecco’s Phosphate Buffered Saline  
3. 1.7 mL microcentrifuge tubes 
4. iScript cDNA Synthesis kit (BioRad) 
5. Taqman Probes (see Table 1) 
 
Protein lysis for western blot 
1. Cell Recovery Solution (Corning) 
2. 1.7 mL microcentrifuge tubes 
3. Dulbecco’s Phosphate Buffered Saline  
4. 2X RIPA buffer: 0.3M NaCl, 0.1M Tris-HcL, 0.05% Sodium Azide, 2% Triton X-
100, 2% Sodium Deoxycholate (w/v), 0.2% Sodium dodecyl sulfate in H2O 
5. Protease Inhibitor Cocktail (Sigma) 
6. Phosphatase Inhibitor Cocktail (Sigma) 
6. Phenylmethylsulfonyl fluoride (PMSF) 
7. 2X RIPA inhibitor buffer: 1% protease inhibitor cocktail, 1% phosphatase inhibitor 
cocktail, and 1 µM PMSF in 2X RIPA buffer 
 
Immunofluorescence analysis – sections 
1. 4% Paraformaldehyde (PFA) in H2O 
2. 30% Sucrose in H20 
3. Parafilm  
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4. 15 mm x 15 mm x 5 mm Cryomold  
5. Optimal Cutting Temperature (OCT) Compound 
6. Dry Ice 
7. Charged Glass Slides (Superfrost Plus) 
 
Immunofluorescence analysis – whole mount 
1. 4% Paraformaldehyde (PFA) 
2. Dulbecco’s Phosphate Buffered Saline (DPBS) 
3. 0.5% Triton X-100 in PBS 
4. 100 mM glycine in PBS  
5. Normal goat serum (NGS) 
6. Immunofluorescence (IF) Buffer: 0.1% BSA, 0.2% Triton X-100, 0.05% Tween-20 
in PBS 
7. Primary and secondary antibodies (end user determined targets) 
8. Parafilm 
9. Optional: Bisbenzimide 
10. Optional: Antifade Media 
 
Preparation of cells for staining and analysis of intracellular markers by flow 
cytometry/FACS  
 
For crypt dissociation flow cytometry/FACS: 
1. Hanks Balanced Salt Solution (HBSS) (Gibco)  
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2. 50 U/mL Dispase 
3. 20,000 U/mL Deoxyribonuclease I (DNase I) from bovine pancreas 
4. Y-27632 (Selleck Chemical) 
5. Disassociation solution: 0.6 U/mL Dispase, and 120 U/mL DNase I, and 10 µM Y-
27632 in HBSS 
6. Fetal Bovine Serum (FBS) 
7. 40 µm cell strainer (Falcon) 
8. Dulbecco’s Phosphate Buffered Saline (DPBS) 
9. 2X ISC Medium (See Note 1) 
 
For Dissociation of organoids for flow cytometry/FACS: 
1. TrypLE Express (Gibco) 
2. Y-27632 (Selleck Chemical) 
3. Water bath set to 37°C 
4. Dulbecco’s Phosphate Buffered Saline (DPBS (1X), Gibco) 
5. 40 µm cell strainer (Falcon) 
6. Dulbecco’s Phosphate Buffered Saline (DPBS (1X), Gibco) 
7. 2X ISC Medium (See Note 1) 
For Intracellular staining for flow cytometry/FACS: 
1. 1% Bovine Serum Albumin (BSA) in 1X DPBS 
2. 4% Paraformaldehyde (PFA) in H2O 
3. Permeabilization buffer: Permeabilization Buffer (10X) (eBioscience) diluted to 
1X in 1% BSA in PBS 
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Serial passaging for functional analysis 
1. TrypLE-Express (Gibco) 
2. Y-27632 (Selleck Chemical) 
3. 1.7 mL microfuge tubes 
4. Advanced DMEM/F12  
5. Extracellular Matrix: Growth Factor Reduced Matrigel or Cultrex 
6. ENR (EGF/Noggin/R-spondin 1) medium (See Note 7) 
 
Methods 
Generating Conditioned Media 
1. Plate Cultrex Rspondin1 293T cells in 15cm tissue culture plate with 20 mL 
Selection media 
2. Allow cells to grow to ~95% confluency, changing media every 2 days 
3. Split cells 1:25 into 25 15cm tissue culture plates with 20 mL Culture media 
4. Allow plates to grow to approximately 50% confluency. Remove Culture media. 
Rinse plates twice with room temperature 1X DPBS. Add 20 mL Harvest media 
to plates. 
5. After ~24 hours, collect media from plates. This is the “first harvest” of 
conditioned media. Filter through 0.22 µm filter into sterile container and store at 
4°C until second harvest. 
6. Add 20 mL Culture media to each plate and allow cells to grow to 80-90% 
confluency. Again, remove culture media. Rinse plates twice with 1XDPBS. Add 
20 mL Harvest media to plates. 
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7. After ~24 hours, collect media from plates. This is the “second harvest” of 
conditioned media. Filter through 0.22 µm filter into sterile container and store at 
4°C. (See Note 8) 
8. After both collections are obtained, combine harvests in a sterile container and 
thoroughly mix.  
9. Aliquot media into 40mL aliquots and store frozen at -80°C. (See Note 9) 
 
Crypt-enriched intestinal epithelial isolation 
1. Prepare and label the following 50 mL conical tubes, one set (a-d) per mouse. All 
tubes should be pre-chilled on ice or at 4°C prior to crypt isolation: 
a. Tube “P”: 10 mL DPBS 
b. Tube “E1”: 10 mL 3 mM EDTA in DPBS 
c. Tube “E2”: 10 mL 3 mM EDTA in DPBS 
d. Tube “S”: 10 mL DPBS 
2. Prepare and label two 10 cm petri dishes containing 10 mL DPBS each, per 
mouse 
3. Euthanize mouse in accordance with institutionally approved humane practices 
4. Clean mouse abdomen around planned incision area using 70% EtOH 
5. Open abdomen with surgical scissors and dissect desired length of intestine (See 
Note 10) 
6. Place dissected intestine in first of two DPBS-containing 10 cm petri dishes 
7. Open intestine longitudinally by cutting down the length of the lumen with sharp 
surgical scissors (See Note 11) 
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8. Rinse opened intestine by gripping tissue with forceps and gently swirling in 
DPBS-containing petri dish to remove fecal matter 
9. Transfer intestinal tissue to Tube “P” using forceps and invert gently 5-10 times 
to remove remaining fecal matter 
10. Transfer intestinal tissue to Tube “E1” and incubate for 15 minutes at 4°C, with 
gentle agitation (See Note 12) 
11. While tissue is incubating in “E1”, prepare a glass plate or dish by cleaning with 
70% EtOH followed by sterile DPBS 
12. Remove tissue from “E1” and transfer to prepared glass plate, positioned so that 
luminal side is facing up 
13. Using a sterile pipette tip, gently “brush” the full length of intestinal tissue, first in 
one direction, then in the opposite direction. This step will remove a majority of 
villus tissue, leaving crypts intact. Avoid brushing too forcefully or for an extended 
period of time in order to preserve crypts (see Figure 5.2B vs Figure 5.2C) 
14. Transfer brushed intestine to second DPBS-containing 10 cm petri dish and rinse 
off remaining villi by gripping tissue with forceps and gently swirling, as in step 8. 
15. Transfer tissue to lid of second DPBS-containing petri dish (lid should not contain 
any buffer) and cut into 2-3 cm pieces using surgical scissors 
16. Transfer intestinal pieces into Tube “E2” and incubate for 35 minutes at 4°C, with 
gentle agitation, as in step 10. 
17. Transfer intestinal pieces into Tube “S” and shake gently for 2-5 minutes to 
remove epithelium (including crypts) (Figure 5.2D). (See Note 13) 
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18. Add 10 mL DPBS to Tube “S” and filter crypt epithelial slurry through 100 µm cell 
strainer into new 50 mL conical to enrich epithelial suspension for crypts (Figure 
5.2E) 
19. Pellet crypts at 500 x g-force, 4°C for 5 minutes 
20. Discard supernatant and resuspend crypt pellet in 250-500 µL 1X ISC media 
21. Prepare three 1:10 dilutions of concentrated crypt slurry and determine average 
number of crypts per 1 µL volume by counting on inverted light microscope (See 
Note 14) 
 
Organoid culture and cytokine treatment 
1. Pre-chill all tubes and tips to be used for handling 3D extracellular matrix (ECM) 
reagent (See Note 15) 
2. Depending on experimental needs, place a 48 well or 96 well plate(s) in cell 
culture incubator to pre-warm to 37°C prior to plating ECM 
3. Prepare the total volume of ECM needed per crypt sample by transferring to a 
1.7 mL conical on ice. (See Notes 16 and 17) 
4. Using crypt concentration previously determined in Section 3.2 Step 21, add 
desired number of crypts to be plated to ECM and mix by gently pipetting to 
disperse crypt slurry evenly in ECM (See Notes 18-20) 
5. Create “bubbles” of crypt-containing ECM by pipetting appropriate volume (10 µL 
for 96 well plate; 20-50 µL for 48 well plate) directly in the center of each well of 
the plate (Figure 5.3A-D) 
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6. Taking care to avoid disturbing freshly-plated “bubbles”, transfer well plate to 
37°C cell culture incubator and allow to polymerize for 15-20 minutes (See Note 
21) 
7. While ECM is polymerizing, prepare ENR media: 250 µL per well of 48 well plate; 
100 µL per well of 96 well plate (See Note 22) 
8. Following polymerization, overlay ECM “bubbles” with appropriate volume of 
media. To avoid damaging ECM, pipet media down the side of each well. Avoid 
pipetting media directly into ECM “bubble” (Figure 5.3E-G) 
9. Complete ENR media should be changed every 48 hours throughout duration of 
organoid cultures 
10. Following organoid establishment, Type-2 epithelial responses (e.g.: goblet and 
tuft cell differentiation) can be induced by the addition of cytokines IL-4 and IL-13. 
We have noted strongest induction of goblet/tuft cell hyperplasia in jejunal 
organoids treated with 100 ng/mL IL-13 (Biolegend), but optimal cytokine 
concentrations should be determined per intestinal segment studied and by 
manufacturer source of recombinant protein. (See Note 23) 
 
RNA lysis and gene expression analysis 
1. To lyse and isolate total RNA from organoid cultures which consist of low 
numbers of cells, we recommend the RNAqueous Micro Kit (Ambion) 
2. Aspirate full volume of media from wells to be lysed using P200 (96 well plate) or 
P1000 (48 well plate) pipette tip. Take care to avoid disturbing ECM bubble 
(Figure 5.3E-G) 
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3. Rinse wells once by adding and aspirating 100 µL (96 well plate) or 250 µL (48 
well plate) 1X DPBS 
4. Lyse organoids in ECM bubbles by adding 200 µL (96 well plate) or 500 µL (48 
well plate) Lysis Buffer (Ambion) directly to center of each well. Allow Lysis Buffer 
to incubate with 3D ECM/organoids for ~5-10 seconds at RT, then collect lysate 
while scraping bottom of well with pipette tip to break up and dissolve any 
remaining solid ECM. 
5. Transfer lysates to 1.7 mL microcentrifuge tubes and prepare RNA as per 
manufacturer instructions, or store at -80°C until RNA isolation 
6. Prepare cDNA and conduct qRT-PCR as per standard laboratory protocols. We 
recommend the iScript cDNA Synthesis kit (BioRad) and Taqman probes for 
cDNA synthesis and gene expression analysis, respectively. (See Note 24) Table 
1 includes the gene names and catalog numbers of Taqman probes 
recommended for validation of Type-2 response in epithelial organoid cultures.  
(See Note 25) 
  
Protein lysis for western blot 
1. Due to the number of crypts required for protein analysis by western blot, we 
recommend using cultures in 48-well plates (250-500 crypts per well) for these 
assays 
2. Aspirate full volume of media from wells to be lysed using P200 (96 well plate) or 
P1000 (48 well plate) pipette tip. Take care to avoid disturbing ECM bubble 
(Figure 5.3E-G) 
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3. Add 500 µL Cell Recovery Solution (Corning) to each well and break up ECM 
patty into recovery solution by scraping bottom of well and pipetting vigorously 
(See Note 26) 
4. Incubate organoids in Cell Recovery Solution with end-over-end rotation for 45 
minutes at 4°C 
5. Pellet organoids at 5,000 x g-force for 5 minutes at 4°C 
6. Aspirate and discard supernatant and rinse organoid pellet twice with 500 µL of 
ice cold DPBS 
7. Lyse organoids in 30 µL 2X RIPA inhibitor buffer  
8. Proceed with western blot analysis as per standard protocol 
  
Immunofluorescence analysis – sections 
1. Aspirate full volume of media from wells to be lysed using P200 (96-well plate) or 
P1000 (48 well plate) pipette tip. Take care to avoid disturbing ECM bubble 
(Figure 5.3E-G) 
2. To fix organoids in ECM, add 100 µL (96-well plate) or 250 µL (48-well plate) 
freshly-prepared, room temperature 4% paraformaldehyde (PFA) and incubate at 
room temperature for 20 minutes (See Note 27) 
3. Aspirate and discard PFA in accordance with chemical safety standards 
4. Rinse each well with 100 µL 30% Sucrose three times to remove any residual 
PFA 
5. Add 100 µL 30% sucrose to each well, wrap well plate in Parafilm to prevent 
evaporation, and store samples for at least 24 hours at 4°C 
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6. Take p200 tip and bend tip to use as a scraping tool. Gently scrape up organoids 
with bent P200 and transfer organoids and sucrose to 1.7mL microfuge tube 
using P200 tip attached to pipette with tip cut to create a larger bore as to not 
break up organoids 
7. Centrifuge at 200 x g for 5 minutes at room temperature to gently pellet 
organoids. Remove as much 30% sucrose as possible without disturbing 
organoids 
8. Fill a cryomold with OCT 
9. Add organoids and sucrose to top left region of OCT in the cryomold, making 
sure not to touch the edges. To evenly distribute organoids within OCT, gently 
swirl the organoids and sucrose in a figure-8 shape to mix the sucrose and OCT. 
(See Note 28) 
10. Freeze organoids in OCT on dry ice and store at -80°C 
11. To section organoids: take a series of ten 8-10 µm serial sections on separate 
slides, then check for sectioned organoids by light microscopy (Figure 5.5). 
When organoid sections are located, take serial sections until full thickness of 
organoid has been sectioned. Repeat until desired number of sections is 
procured. (See Note 29) 
12. Proceed with standard immunohistochemical or immunofluorescent analysis, or 
store slides at -80°C until use. Examples of immunofluorescent staining for 
DCLK1 (Tuft cells, ), MUC2 (Goblet cells, Santa Cruz, Cat#sc-15334, 1:500), and 
LYZ (Paneth cells, Diagnostic Biosystems, Cat#RP028, 1:500), are in Figure 5.6. 
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Immunofluorescence analysis – whole mount 
1. Aspirate full volume of media from wells to be lysed using P200 (96 well plate) or 
P1000 (48 well plate) pipette tip. Take care to avoid disturbing 3D ECM bubble 
(Figure 5.3E-G) 
2. Fix organoids in ECM by adding 100 µL (96 well plate) or 250 µL (48 well plate) 
freshly-prepared, room temperature 4% PFA and incubating at room temperature 
for 20 minutes. 
3. Aspirate and discard PFA in accordance with chemical safety standards 
4. Rinse fixed wells three times with 100 µL PBS 
5. Add 100 µL 0.5% Triton X-100 in PBS to permeabilize organoids and incubate at 
RT for 20 minutes 
6. Aspirate permeabilization buffer and rinse wells twice with 100 mM glycine in 
PBS, 15 minutes at RT for each wash 
7. Add 100 µL of 10% NGS in IF Buffer to each well and incubate at RT for 90 
minutes to block nonspecific antigen binding 
8. Add 100 µL of primary antibody diluted in 10% NGS in IF Buffer, wrap plate in 
Parafilm to prevent evaporation, and incubate overnight at 4°C 
9. Aspirate primary antibody and wash each well three times in IF Buffer at RT, 20 
minutes per wash 
10. Add 100 µL of secondary antibody diluted in 10% NGS in IF Buffer, incubate at 
RT for 2 hours 
11. Aspirate secondary antibody and wash each well three times in IF Buffer at RT, 
20 minutes per wash 
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12. OPTIONAL: To detect nuclei, dilute bisbenzimide 1:1000 in 1X DPBS and add to 
wells for 20 minutes at RT 
13. Wash wells three times with an excess of 1X DPBS 
14. Add 1X DPBS or antifade media to wells and image samples immediately 
  
Analysis by flow cytometry 
If analyzing primary intestinal crypts, follow methods in Methods Section 3.1 to 
isolate crypts, then proceed to: Dissociation of crypts for flow cytometry/FACS (3.8.1) . If 
analyzing organoid cultures, proceed to: Dissociation of organoids for flow 
cytometry/FACS (3.8.2) . If analyzing with intracellular antibodies and fixation is 
necessary for analysis, proceed to Intracellular staining for flow cytometry/FACS (3.8.3) 
after isolating single cells from either described method. 
 
Dissociation of crypts for flow cytometry/FACS: 
1. Pellet crypts at 1,800 x g-force for 5 minutes at 4°C 
2. Resuspend crypt pellet in 1 mL HBSS, then add to 9 mL of Dissociation solution  
3. Place tube in 37°C water bath for 10-15 minutes, shaking vigorously for 30 
seconds every 2 minutes  
4. After each shake, observe 10 µL aliquot of solution to assess extent of 
dissociation to single cells (See Note 30) 
5. Once dissociation is complete, add 1 mL FBS to tube and place on ice 
6. Filter cells through 40 µm cell strainer directly into 50 mL conical containing 5 mL 
ice cold sterile 1X DPBS 
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7. Pellet cells at 1,800 x g-force for 5 minutes at 4°C 
8. Wash three times with 15 mL ice cold sterile DPBS 
9. Resuspend in 1X ISC media with 10 µM Y-27632 
10. Stain cells with antibodies at proper concentration for 1 hour on ice with gentle 
agitation 2-3 times/hour (See Notes 31 and 32) 
11. Rinse twice with ice cold 1X DPBS, centrifuge at 1,800 x g-force for 5 minutes at 
4°C 
12. Resuspend in 1X ISC media with 10 µM Y-27632 and perform flow 
cytometry/FACS 
 
Dissociation of organoids for flow cytometry/FACS: 
1. Remove media from each well and add 100 µL (for 96 well plate well) of TrypLE 
Express with 10 µM Y-27632. 
2. Break up enteroids and ECM with P200 tip by scraping bottom of well and 
pipetting up and down 30 times 
3. Pool all wells of cells in 5 mL of pre-warmed TrypLE Express buffer with 10 µM 
Y-27632 
4. Place tube in 37°C water bath for 10-15 minutes. Shake tube every 1-2 minutes 
for 30 seconds. After each shake, observe 10 µL aliquot of solution to judge 
dissociation of crypts to single cells. 
5. Filter cells through 40 µm cell strainer directly into 50 mL conical containing 5 mL 
ice cold sterile 1X DPBS. 
6. Pellet cells at 1,800 x g-force for 5 minutes at 4°C 
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9. Wash three times with 15 mL ice cold sterile 1X DPBS 
10. Resuspend in 1X ISC media with 10 µM Y-27632 
11. Stain cells with antibodies at proper concentration for 1 hour on ice with gentle 
agitation 2-3 times/hour (See Notes 31 and 32) 
12. Rinse 2 times with ice cold 1X DPBS, centrifuge at 1,800 x g-force for 5 minutes 
at 4°C 
13. Resuspend in 1X ISC media with 10 µM Y-27632 and perform flow cytometric 
analysis 
 
Intracellular staining for flow cytometry/FACS: 
1. Bring single cells to concentration of 10 million cells/mL in 1% BSA in PBS 
2. If using a surface antibody, apply now and incubate for the appropriate time and 
temperature for your antibody (See Note 32) 
3. Wash cells with 3 mL 1% BSA in PBS, spin down, aspirate supernatant 
4. Place 100 µL of RT 4% PFA on pellet and gently pipette up and down 10X to 
mix. Incubate for 15 minutes at RT 
5. Wash cells with 3 mL 1% BSA in PBS, spin down, aspirate supernatant 
6. Add optimized concentration of intracellular antibody to 100 µL of 
Permeabilization buffer and place on cell pellet, pipette up and down to mix, 
incubate for 30 minutes at RT protected from light 
7. Wash cells twice in 3 mL Permeabilization buffer, spin down, aspirate 
supernatant 
8. Resuspend in 500 µL 1% BSA in PBS for analysis by flow cytometry/FACS 
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Serial Passaging for functional analysis 
1. Count number of living organoids in each well, record 
2. Remove media from each well 
3. Add 250 µL TrypLE Express with 10 µM Y-27632 to each well of 48 well plate 
4. Scrape up each ECM bubble, pipette up and down 75 times to dissociate ECM 
and organoids, and transfer to 1.7mL tube containing 250 µL TrypLE Express 
with 10 µM Y-27632 
5. Place in 37°C water bath for 2.5 minutes 
6. Pipette cells up and down 20 times 
7. Place in 37°C water bath for 2.5 minutes 
8. Add 1 mL ice cold Advanced DMEM/F12 and place tube on ice 
9. Centrifuge at 2,000 x g-force for 5 minutes to pellet cells 
10. Carefully remove supernatant and add appropriate amount of ECM to each tube 
on ice (See Note 33) 
11. Pipette up and down at least 50 times to resuspend cells within ECM and plate 
as directed in Section 3.3 (Organoid culture and cytokine treatment) 
12. Allow ECM bubbles to polymerize for 15-20 minutes in 37°C incubator 
13. Overlay ECM bubbles with 250µL ENR media (See Note 34) 
14. Allow organoids to grow in culture for 7-10 days, then record number of living 
organoids present in each well. This number reflects the increase in organoid 
number after passaging. If necessary, repeat passaging procedure until number 
of required serial passages is completed. (See Note 35) 
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Notes 
1. Media can be made 1X by adding equal volume of Advanced DMEM/F12 to 2X 
ISC media. 
2. Other tissue culture plates may be incompatible with Matrigel/Cultrex due to the 
surface charge after plastic treatment. 
3. Both commercially available matrices have been used to successfully grow 
intestinal organoids. To our knowledge and at the time of this publication, no 
studies quantifying differences in organoid performance using each matrix exist.  
4. Recombinant Mouse R-spondin1 (250 µg/mL, R&D Systems) can be used 
instead of conditioned media, but conditioned media is thought to be more 
biologically active. 
5. Y-27632 is included for first 48 hours of culture only. 
6. 50 µg/mL Primocin (Invivogen, 1,000X of 50 mg/mL stock) can be added to 
media if concerned about contamination at time of crypt isolation and organoid 
establishment. Primocin is included for first 48 hours of culture ONLY. Primocin 
can also be used at 100 µg/mL (500X) if contamination persists with 50 µg/mL 
concentration.  
7. Optional: To encourage single cell growth, cultures receive 0.3 nM CHIR-99021 
and 100 nM Valproic Acid for the first two days in culture only. 
8. Cells can be discarded or frozen back down for storage in Freezing media and 
subsequently used to make additional batches of conditioned media. 
9. Protein activity in conditioned media can be determined by commercially 
available ELISA or protein activity assays, as desired. 
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10. Regional differences in gene expression, morphology, and performance in 
epithelial prep and crypt culture have been noted between duodenum, jejunum, 
and ileum. It is important to control for portion of intestine used when planning 
crypt isolation and culture experiments. 
11. Fine iris scissors produce best results when opening intestines. 
12. Agitation on a rocking platform is recommended. 
13. Shaking force and time will affect quality and extent of crypt yield and must be 
determined empirically by each user. We recommend examining progress of 
crypt isolation from intestinal tissue by removing 10µL aliquots from Tube “S” at 
1min intervals to check for the presence of intact, well-separated crypts. If crypt 
yield is especially low, remnant intestinal tissue can be fixed and examined by 
histology for the presence of un-released crypts. 
14. To prevent drying of aliquots while counting, we recommend pipetting each 1:10 
dilution into a separate region of a 10 cm petri or cell culture dish. 
15. Pre-chilling tubes and tips is optional, but recommended for users who are new 
to Matrigel or Cultrex. Both reagents have been used successfully by a number 
of groups; this protocol will refer to Matrigel and Cultrex collectively as “ECM”. 
End users are encouraged to test reagents empirically and decide which is best 
for their projects.  
16. For experiments in 48 well plates, we recommend 20-50 µL of ECM per well 
(depending on number of crypts plated); for experiments in 96 well plates, we 
recommend 10 µL of ECM per well. 
17. We recommend plating crypts at a density of 5-10 crypts/µL of ECM. 
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18. Take care to avoid introducing bubbles in ECM; never pipet past first stop on 
pipette. 
19. Addition of crypt slurry will dilute ECM, so using a very concentrated crypt 
sample will reduce the amount by which ECM is diluted. We strongly recommend 
avoiding dilution of ECM past 50%. 
20. We recommend a crypt density of ~50-100 crypts per 10µL droplet in 96 well 
plate and 250-500 crypts per 50 µL droplet in 48 well plate. Plating crypts too 
densely will result in poor survival of organoid cultures. 
21. Polymerization may take longer than 15min depending on dilution factor of ECM. 
In our experience, crypts can be left in polymerized ECM at 37°C for up to 45 min 
without any notable loss in organoid-forming ability. 
22. To account for pipetting error, we recommend preparing 0.5 well volume more 
than needed. 
23. Organoids are considered “established” when they start developing well-defined 
crypt-like buds (Figure 5.4). The appropriate culture timepoints for organoid 
establishment, expansion, and cytokine treatment should be determined 
empirically based on the needs of the experiment. We recommend allowing 
 organoids to establish in culture for at least 48 hours prior to treatment, to 
allow for removal of anoikis inhibitor Y-27632. 
24. cDNA prepared from RNA lysates of 50-100 organoids per 96 well plate performs 
well in qRT-PCR assays when diluted in a range of 1:5-1:10.  
25. We recommend using Muc2 and Dclk1 as controls for goblet and tuft cell 
hyperplasia, respectively, and Lyz2, Chga, and SI to validate that Paneth, 
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enteroendocrine, and absorptive enterocyte lineages remain unaffected by 
cytokine treatment. 
26. Cell Recovery Solution is critical to eliminate as much ECM as possible prior to 
crypt lysis. Residual ECM will affect total protein assays and may affect western 
blot results, depending on proteins of interest. 
27. Avoid adding cold PFA to plates, as this can compromise integrity of ECM and 
result in loss of organoids.  
28. Evenly mixing fixed organoids into OCT is important for downstream sectioning; if 
organoids are not evenly distributed within the cyromold, it will be more difficult to 
acquire high quality sections. 
29. Organoid sections are not visible by naked eye unless organoids are very large 
at time of processing. Examining serial sections by microscopy is essential for 
obtaining sectioned tissue.  
30. Many factors can cause differences in the length of time it takes for crypt 
dissociation, including mouse age/genotype, intestinal region, or treatment. We 
recommend constantly checking each sample for single cell dissociation. 
31. If staining for live/dead discrimination, vital dyes should be added immediately 
before running samples on flow cytometer/FACS instrument. 
32. Antibodies and antibody concentrations must be empirically determined by end 
user. 
33. The amount of ECM to cells is dependent on experimental conditions and size of 
plate; we recommend 20-25µL for each well of a 48 well plate and 8-10µL for 96 
well plate. 
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34. To encourage single cell growth, cultures receive 0.3 nM CHIR-99021 and 100 
nM Valproic Acid for the first two days in culture only. 
35. Organoids will eventually become very crowded within each well, so we suggest 
keeping organoid concentration similar across treatments and passages by 
increasing the passaging ratio (1:2, 1:4, etc) as cultures become crowded. It is 
important to record this passaging ratio to accurately reflect number of organoids 
resulting from serial passaging even if all organoids are not plated/counted. 
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Figure 5.1 A cellular mechanism to resolve helminth infections in the 
gastrointestinal tract. Upon parasitic infection, Tuft cells detect the presence of 
helminths or protozoa chemosensory pathway. Tuft cells respond by secreting IL-25 that 
in turn acts on submucosal ILC2 cells (A), which secrete IL-13 (B).  ILC2 cells are in close 
proximity to the stem/progenitor cell compartment and the IL-13 secreted by ILC2 cells 
promotes lineage bias toward Tuft and Goblet cells (C, D). Goblet cell hyperplasia has a 
dual function to increase mucous to protect the epithelium and aid in worm clearance, 
while Tuft cell hyperplasia serves to increase sentinels to monitor and respond to the 
worm infection. Increases in Tuft cell numbers continue to fuel the IL-25 positive feedback 
during infection (E). Reduction in worm burned serves as a break to Tuft and Goblet cell 
hyperplasia and the epithelium returns to homeostasis (F). 
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Figure 5.2 Quality control steps in intestinal crypt isolation. Crypt-enriched epithelial 
preparations should be monitored by light microscopy at several critical steps in order to 
ensure high quality isolation (A). First, gentle “brushing” of intestinal tissue following an 
initial 15 minutes incubation in 3mM EDTA removes a majority of villi (B). Care should be 
taken to avoid over brushing or applying too much force while removing villi, as this will 
displace crypts as well (C). Further incubation in 3mM EDTA for 35 minutes, followed by 
shaking of intestinal tissue in DPBS yields a mixed fraction of crypts and villi (D). Finally, 
filtering the mixed crypt/villus epithelial “slurry” through a 100 µm cell strainer enriches for 
the crypt fraction, which can be used for crypt culture of further dissociated to single cells 
for analysis by flow cytometry (E).   
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Figure 5.3 Best practices for placing ECM, and adding/removing media from ECM-
based cultures. ECM plating technique and media change instructions. (A) Start with the 
pipette tip touching center of the well base. (B) While gently ejecting the ECM, slowly 
raise the pipette tip from the well base. (C & D) Leaving a small amount of ECM in the 
pipette tip to not introduce bubbles, remove the pipette tip straight up out of the ECM 
patty. (E) We recommend adding media by gently pipetting down the side of the well 
plate, to avoid direct contact with the ECM. (F) To aspirate media prior to media changes, 
pipet tips can be placed in contact with the base of the well, adjacent to the ECM. (G) 
Care should be taken to avoid making direct contact with the ECM either by pipet tip or 
forceful ejection of media, as this can compromise the structure of the ECM and result in 
loss of organoids. 
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Figure 5.4 Organoids in culture form crypt buds. After 24-hours in culture, crypts ball 
up to form spheres (A). After 3-7 days in culture, organoids develop well-defined crypt-
like buds (arrow) (B).  
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Figure 5.5 Sectioned organoids can be identified by light microscopy. Following 
sectioning, organoids can have the appearance of dust/debris (A). When rehydrated for 
immunofluorescence staining, characteristic epithelial morphology is observed (B).  
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Figure 5.6 Wild-type intestinal organoids contain tuft, goblet, and Paneth cell 
populations. Canonical markers for tuft cells (DCLK1, A), goblet cells (MUC2, B), and 
Paneth cells (LYZ2, C) can be used to assess secretory cell numbers in intestinal 
organoids by immunofluorescence.  
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Gene Name Cell Type TaqMan Gene Expression Assay ID 
18S Housekeeping Gene Hs99999901_s1 
ChgA Enteroendocrine Cells Mm00514341_m1 
Dclk1 Tuft Cells Mm00444950_m1 
Lyz2 Paneth Cells Mm00727183_s1 
Muc2 Goblet Cells Mm00458299_m1 
SI Absorptive Enterocytes Mm01210305_m1 
Table 5.1 Suggested Taqman probes for qRT-PCR analysis 
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